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Executive summary 

Background:
While chemotherapy-related vomiting is relatively well-controlled with current antiemetics, nausea remains a significant problem for patients and a difficult symptom for clinicians to manage. The role of complementary therapies, and particularly acupressure at the P6 (Neiguan) point, as adjunctive treatments to pharmacological antiemetics has been investigated in a number of studies in the past. Both positive and negative results have been reported in the literature, providing evidence of highly suggestive but not conclusive results. Many past studies, however, are hampered by methodological problems, including small sample sizes, minimal control of risk factors for chemotherapy-related nausea and vomiting and no control of the antiemetic drugs used. Hence, there  is a need to clarify whether acupressure is effective and cost-effective in the management of chemotherapy-related nausea and vomiting using a robust methodological design with well-powered sample size.

Objectives: 
Primary objective:
1.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
Secondary objectives:
2.	To assess the cost effectiveness and extent of use of usual care in patients using acupressure wristbands in addition to standard care for the management of chemotherapy-induced nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
3.	To assess the level of quality of life in patients using acupressure wristbands in addition to standard care in the management of chemotherapy-induced nausea and vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
4.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
5.	To ascertain for which emetogenic level of chemotherapy regimens (ie. high, moderate or low emetogenic chemotherapy) self-acupressure using wristbands in addition to standard care is more or less effective in terms of nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
6.	To ascertain whether any improvement in chemotherapy-induced nausea and vomiting from using acupressure wristbands is different in males and females.
7.	To ascertain whether there is an age effect from the use of acupressure wristbands in relation to chemotherapy-induced nausea and vomiting.

Methods:
A randomised three-group sham-controlled trial was designed to test the effects of acupressure in the management of chemotherapy-related nausea and vomiting. Patients with heterogeneous cancer diagnoses receiving low, moderate and highly emetogenic chemotherapy were randomised to receive, in addition to standardised antiemetics,  either acupressure wristbands, sham acupressure wristbands or antiemetics alone. The randomisation method used consisted of minimisation with a random element (stochastic minimisation), balancing for gender, age (16-24; >24-50; >50) and three levels of emetogenic chemotherapy (low, moderate and high according to international ASCO and MASCC classifications). Patients were instructed to wear the wristbands throughout the day for the first 7 days during each cycle of chemotherapy. Primary outcome assessment was carried out daily for 7 days per chemotherapy cycle over four cycles using the Rhodes Index for Nausea & Vomiting. Other assessments, completed at day 6 of each of the four cycles, included the MASCC Antiemesis Tool, EQ-D 5 Utility scale and the FACT-G quality of life scale. At baseline participants completed measures of anxiety and depression, of nausea/vomiting expectation and expectations from using the acupressure wristbands. An economic evaluation was also carried out based on drug and health service utilisation from the perspective of the health and social care provider and presenting incremental cost-effectiveness ratios with quality-adjusted life years as the outcome. Finally, a nested qualitative interview study was incorporated to shed more light into the quantitative findings.

Results:
500 patients were randomised in the three study groups. Primary outcome analysis (nausea in cycle 1) revealed no statistically significant differences between the three groups, although nausea levels in the proportion of patients using wristbands (both real and sham ones) was somewhat lower than in the antiemetics only group (median nausea experience score over the 4 cycles of 1.43, 1.71, 1.14, 1.14 respectively in the standard care arm, 0.57, 0.71, 0.71, 0.43 in the sham acupressure arm respectively and 1, 0.93, 0.43, 0 in the acupressure arm respectively. Adjusting for gender, age and emetic risk of the chemotherapy, the odds ratio (O.R.) of lower nausea experience was 1.18 for the acupressure group and 1.42 for the sham acupressure group. A gender interaction effect was evident in the data (P=0.002), with females responding more favourably to the use of sham acupressure wristbands  than males (O.R.=0.35 in males and 2.02 in females in the sham group; 1.27 in males and 1.17 in females in the real acupressure group). This suggests a placebo effect. No significant differences were detected in relation to vomiting outcomes, anxiety, and quality of life measures. The cost-effectiveness evaluation revealed no significant differences (t-tests) between the costs in each arm.Total costs (all drugs and NHS costs) were £70.66 for the acupressure group, £111.13 for the standard care group and £161.92 for the sham acupressure group. However caution is needed in interpreting these results due to very small changes in utility and the influence of a few high cost outliers. Twenty-six subjects from all three groups took part in in-depth qualitative interviews. Four themes emerged from the data, including ‘Deciding to participate’, ‘Perceptions and experiences of complementary therapies’, ‘Experience of taking part in the trial’, and ‘Experience of using the wristbands’. The qualitative data overall suggested that the participants perceived the wristbands (both real and sham ones) as effective and helpful to manage their nausea experience during chemotherapy. Minor and transient side effects from the use of the wristbands were observed.

Conclusions
No clear recommendations can be made about the use of acupressure wristbands in the management of chemotherapy-related nausea and vomiting, as results did not reach statistical significance. However, these differences observed may be of clinical importance for the patients and potentially lead to lower health care utilisation. The use of wristbands was also safe and perceived to be effective by the patients. Before rejecting this intervention we need to consider the therapeutic effect of placebos in situations such as in the management of nausea when otherwise low-cost and safe intervention may enhance the effect of antiemetic drugs. The study provided evidence of encouraging signals in relation to improved nausea experience and and a suggestion of potential health resource use benefits to warrantee further consideration both in practice and in further clinical trials.
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1.	Literature review
1.1.	Existing research
Significant developments in antiemetic therapy over the past two decades have improved the control of chemotherapy-related vomiting. By contrast, chemotherapy-related nausea, both acute and delayed, is still a significant problem in clinical practice, with 42–52% of patients experiencing nausea on any one day in routine practice1. Surprisingly, despite improvements in the management of vomiting, post-chemotherapy nausea seems to have increased2. Furthermore, clinicians often underestimate the experience of nausea, especially with regards to delayed nausea3,4.

Chemotherapy-induced nausea and vomiting (CINV) can have a profound effect on the cancer treatment experience5 and is associated with negative effects on daily life and overall quality of life, including effects on food intake, weight loss, effects on social interactions, dehydration, difficulty with sleeping and anxiety5,6. In a qualitative study of patients’ experiences, unmanaged nausea was constant in some patients and made them exhausted for long periods after chemotherapy, making recovery between cycles longer5. The impact of nausea is greater than that of vomiting7 and nausea has proven to be more difficult to control. The direct and indirect costs of the experience of nausea and vomiting, especially of delayed symptoms, are considerable8. Antiemetic trials have traditionally focused primarily on vomiting and emetic episodes, upon which the effectiveness of many antiemetic drugs is judged. Little attention has been directed to the concept of chemotherapy-induced nausea despite the fact that it is increasingly recognised that nausea and vomiting are related but separate entities9,10.  The need for these two symptoms to be treated as two separate entities is strongly advocated10.  

The reasons behind this incomplete management of chemotherapy-induced nausea and vomiting  are multifaceted. They include health professionals’ limited understanding of the complex concept of chemotherapy-induced nausea and vomiting and its different phases; limited assessment in clinical practice of chemotherapy-induced nausea and vomiting and its risk factors; using more emetogenic chemotherapy protocols than in the past; not understanding clearly all the pathways involved in the development of chemotherapy-induced nausea and vomiting; and more focus given to the vomiting experience than nausea in clinical trials11.

As antiemetic medications do not fully control nausea during chemotherapy, non-pharmacological interventions in addition to antiemetics have been tested over the years, especially in the 1980s, including relaxation techniques, coping preparation, imagery, and distraction techniques, with positive results in most studies (for a full review see reference 12). Acupuncture and its non-invasive form of acupressure have been tested several times after the classic early work of Dundee13,14. In a literature search of Medline, PubMEd and CINAHLusing the key words ‘acupressure’, ‘nausea’, ‘vomiting’, ‘emesis’, ‘chemotherapy’, ‘cancer’ and combinations, between 1990 and May 2005, we have identified 10 studies specific to oncology, reported elsewhere15, with 7/10 studies showing positive results and a further two approaching statistical significance. These studies have used a variety of acupressure methods, such as the ‘ReliefBand’ (a small battery-operated TENS device designed to stimulate the P6 acu-point) 16-18; an acupressure wristband ( a small elastic band with a round plastic button applying constant mild pressure on the P6 acu-point) 19-21; direct pressure on the acu-point P622 (Shin et al, 2004) or P6 and ST36 points together23. Most studies had small sample sizes of 18-50 patients. The largest study to date (n=739) testing acupressure and acustimulation showed improvements in nausea and vomiting in men while there was a similar trend in women to reduce acute symptoms only, although the latter did not reach statistical significance24. No improvement in nausea/vomiting was shown in a small study by Roscoe et al25 in women with breast cancer using acustimulation (ReliefBand) wristbands. The latter two studies are suggestive of a possible gender effect. However, most past studies are hampered by small sample sizes, the wide variety of (non-standardised) antiemetics used, differences in the risk factors for nausea and vomiting in these samples, the range of emetogenicity of chemotherapy regimens used and sampling issues. A recent Cochrane systematic review of the literature highlights that acupressure reduces acute nausea but not delayed nausea, and has no benefit for vomiting26. However, the review was primarily focused on acupuncture rather than acupressure, all different methods of acupressure were examined together and the results regarding specifically vomiting are questionable (as many of the studies included in the review had samples with little, if any, vomiting across experimental and control groups).

1.2.	 Our own work
Over the past 8 years the lead applicant has developed a programme of research in the management of chemotherapy-induced nausea and vomiting that feeds into the current application. This has involved the assessment of the effectiveness of non-pharmacological interventions for the management of chemotherapy-induced nausea and vomiting including progressive muscle relaxation training and imagery techniques27 ; pilot testing of acupressure15; identification of risk factors for chemotherapy-induced nausea and vomiting development such as age, gender and anxiety28,29; the management of anticipatory nausea and vomiting30;31, the development of international clinical guidelines for managing chemotherapy-induced nausea and vomiting 32,33 and radiation-induced nausea and vomiting34,35; exploration and further clarification of the concept of chemotherapy-induced nausea as a separate entity from vomiting36, the assessment of chemotherapy-induced nausea and vomiting levels in current clinical practice in the UK37,38 and the development of a chemotherapy-induced nausea and vomiting relevant clinical scale for the assessment of acute and delayed symptoms39. The latter is the only chemotherapy-specific scale available to date. In our qualitative study of the experience of chemotherapy-related nausea in seventeen patients with cancer in the UK and USA, nausea was described as distressing and complex symptom36. Preliminary evidence indicates that nausea is part of a cluster of symptoms. Self-management techniques, such as dietary strategies and distraction techniques were rooted in participants’ understanding of nausea and their beliefs about what caused nausea. While self-management was common in almost all patients, acupressure was not one of the approaches used. In an observational prospective evaluation using patient self-reports, 102 patients with cancer receiving their first chemotherapy treatment participated37. Participants were followed up for 4 cycles of chemotherapy, providing a total of 272 assessments of nausea and vomiting. Results indicated that acute vomiting was experienced by 15.7% of the patients in cycle 1 and delayed vomiting by 14.7%, while acute nausea was present in 37.3% of the patients and delayed nausea in 47.1%, which increased over the four cycles. Moderately emetogenic chemotherapy had the highest incidence of chemotherapy-induced nausea and vomiting and acute symptoms were more controlled than delayed symptoms. The data suggested that, while vomiting is relatively well controlled, nausea is a significant problem in practice; it also highlighted the high cost of inappropriate use of antiemetics, which was £17,524 for every 100 patients treated over 4 cycles37.

2.	Research objectives
Primary objective:
1.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
Secondary objectives:
2.	To assess the cost effectiveness and extent of use of usual care in patients using acupressure wristbands in addition to standard care for the management of chemotherapy-induced nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
3.	To assess the level of quality of life in patients using acupressure wristbands in addition to standard care in the management of chemotherapy-induced nausea and vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
4.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
5.	To ascertain for which emetogenic level of chemotherapy regimens (ie. high, moderate or low emetogenic chemotherapy) self-acupressure using wristbands in addition to standard care is more or less effective in terms of nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
6.	To ascertain whether any improvement in chemotherapy-induced nausea and vomiting from using acupressure wristbands is different in males and females.
7.	To ascertain whether there is an age effect from the use of acupressure wristbands in relation to chemotherapy-induced nausea and vomiting.

3.	Research methods
3.1.	Design of the study
The design of the study was a randomised controlled trial with 3 arms. Each arm consisted of usual care plus one of (1) self administered acupressure wristbands, (2) sham acupressure wristbands, and (3) no additional treatment. The duration of the patients’ involvement was for four cycles of chemotherapy, as after 4 cycles patients not responding to the given chemotherapy may discontinue it, may be offered a different chemotherapy regimen, a different treatment plan or may be offered supportive care only.

Subjects were allocated to the trial groups through computer-generated randomisation carried out remotely by the trials unit of the Christie Hospital NHS Foundation Trust. The randomisation method used consisted of minimisation with a random element (stochastic minimisation), balancing for gender29,40, age (16-24; >24-50; >50)29,41 and three levels of emetogenic chemotherapy (low, moderate and high according to international ASCO and MASCC classifications)32,42.

Biases were minimised through: a) carefully developed inclusion and exclusion criteria that take into consideration the range of factors and sources of nausea and vomiting in cancer patients other than chemotherapy (ie. intestinal obstruction); b) the use of covariates for variables that are closely linked with nausea and cannot be excluded as they are present in a large proportion of the population (ie. anxiety) 29,43, to be incorporated during the data analysis as a covariate in ANCOVA models; and c) the use of stratification for other key risk factors for nausea development during chemotherapy (ie. age, gender) at the randomisation stage. Stratification, prior to randomisation, is important to ensure that known prognostic factors are equally distributed before measuring the treatment-related variables.

3.2.	 Pilot study using this design
We had carried out a two-arm pilot study of 36 breast cancer patients using acupressure wristbands (plus antiemetics) versus standard antiemetics only15. The present trial has been based on methods tested in this pilot study. While it is acknowledged that this study was limited, key findings suggested that acupressure improved the nausea experience as well as nausea and vomiting occurrence and distress across the first five days of chemotherapy. Nevertheless, improvements were higher in relation to nausea than vomiting. Mean percentage of improvement was 44.5% in the experimental subjects over the control subjects. The study showed that an acupressure trial is feasible, with high levels of compliance (only 1 patient stopped using wristbands due to arm swelling), although one-third of the patients did not return completed assessments. The lack of follow up techniques (ie. reminder letters), which was due to time constraints, is partly responsible for this figure, and it is acknowledged as a limitation of the pilot study. However, missing data in the returned assessments was almost non-existent, and patient logs for acupressure usage were fully completed.

The use of sham acupressure and acupressure have also been used in another pilot trial we have carried out recently for the management of cancer-related fatigue44, and it was shown that patients in the sham group who were informed they were receiving one of two combinations of (acu)-points were blinded until the end of the trial and that this group had little improvement compared to the real acupressure group, suggesting that this technique was a credible placebo and thus capable of minimising the likely effect of placebo on the study’s findings. 

3.3.	 Interventions, both experimental and control
The design of the study involved a phase III pragmatic randomised trial. 
Sample: The target population was a heterogeneous group of cancer patients meeting inclusion criteria and about to receive chemotherapy of high, moderate and low emetogenic potential. Heterogeneity is important in order to address issues of response to different types of emetogenic chemotherapy, and by gender and age, as past literature highlights these are important in assessing the effectiveness of treatments for chemotherapy-related nausea and vomiting. Minimally emetogenic chemotherapy was not included, as clinical guidelines recommend no antiemetic treatment and the nausea/vomiting level is <10%.

In the acupressure group, in addition to standard antiemetics, patients were provided with a pair of widely available acupressure wristbands . These bands are elastic wristbands with a 1cm protruding round plastic button (stud). These are available in two sizes, a standard one and a larger one. Patients wore the wristband with the stud pressing the P6 acu-point, which is located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis. Patients were provided with a pair of acupressure wristbands and they were instructed to wear them on both arms and take them off only when showering/bathing. An instruction sheet with a picture of point P6 and how to locate the point was also provided to patients. Patients were instructed to wear the wristbands from the morning before chemotherapy administration and for the subsequent 6 days (total=7 days). No other complementary therapies use was recommended during the course of acupressure (although any such use was documented). 

In the sham acupressure group, in addition to standard antiemetics, patients were provided with a pair of the identical appearing wristbands, with the only difference being that the sham wristband had the button was in the exterior of the wristband and patients were instructed to wear the wristband with the button away from what is the P6 point. There had been an ongoing scientific debate on what constitutes an appropriate sham treatment, and it had been acknowledged that there was no sham method in acupuncture and acupressure studies that could be widely accepted as the optimal method. It was increasingly believed that sham acupuncture/acupressure designs cannot detect the whole placebo effect and may generate false negative results45-48, depending on the method used. We had debated the appropriateness of other sham methods, but either they were not blinded enough for the purposes of the trial (ie. had to be slightly dissimilar to real acupressure wristbands) or could be perceived as treatments themselves (ie. acupressure at other points in the forearm or elsewhere where we had no information as to an effect on the experience of nausea). Patients in the clinics could also talk to each other and realize they have different interventions or check the P6 point on the internet. Hence, we resolved to use an acupressure technique which appeared to be exactly the same as the active treatment with the only exception being the place of stud in the wristband (interior or exterior to the band) used. This was also agreed by practitioners too, who had been consulted about their views on the most appropriate sham method. Furthermore, while it was acknowledged that many patients may have heard of the use of such wristbands, the results of our pilot study suggested that their knowledge of acupressure wristbandswould be limited15. In addition, the results of our qualitative study on self-management of chemotherapy-induced nausea and vomiting suggested that acupressure was not commonly used by patients36. An assessment of blinding at the end of the trial was not conducted as patients had not been informed of the use of both sham and real acupressure bands during the trial, but had instead been informed that two different types of wristbands were being evaluated in the trial, with the approval of the Ethics Committee. Clinicians did not know the patients’ group allocation.

The control group received standard antiemetics alone. Standard antiemetics for all three groups were based on ASCO and MASCC international antiemetic guidelines with the exception of NK1 receptor antagonists (ie. aprepitant) recommended in highly emetic chemotherapy, which was not available in the NHS. Hence, for highly emetic chemotherapy, patients received a 5-HT3 receptor antagonist (ie. Zofran 8mg) and dexamethasone 8mg intravenously before chemotherapy and the same orally for 3 days post chemotherapy; for moderately emetogenic chemotherapy a 5-HT3 receptor antagonist (Zofran 8mg) and dexamethasone 8 mg intravenously before chemotherapy and a 5-HT3 receptor antagonist or dexamethasone (preferred) for 2 days post-chemotherapy; and for low emetogenic chemotherapy dexamethasone 8mg before chemotherapy and no other treatment post chemotherapy32,42. All patients received rescue antiemetics if nausea and/or vomiting was persistent and failed to respond to the antiemetic treatment (ie. severe nausea or >5 vomiting episodes), based on the experience of each clinician (as agreed guidelines for rescue antiemetics had not been developed to date).

3.4.	 Inclusion/exclusion criteria
Inclusion criteria:
Patients scheduled to receive their first chemotherapy cycle
Patients scheduled to receive highly, moderately and low emetogenic chemotherapy (as per ASCO and MASCC classifications)
Patients scheduled to receive a chemotherapy regime given as a single or multiple administration repeated in 2, 3 or 4-week cycles
Patients who were acupressure wristband-naïve (in terms of never having tried for themselves such a wristband, although they may have seen or heard about such wristbands)
Patients of either gender and older than 16 years old
Patients with any cancer diagnosis receiving chemotherapy without concurrent use of radiotherapy 
Patients receiving chemotherapy as outpatients or inpatients
Patients who were willing to participate in the study and be randomised into one of the three study groups

Exclusion criteria:
Patients scheduled to receive radiotherapy concurrently with chemotherapy and during the assessment period of four cycles for each patient
Patients unable to self care (ie. unable to use wristbands appropriately; mental incapacity preventing continuous and optimal use of wristbands) as judged by the investigators
Patients with liver disease (as nausea is common presenting symptom)
Patients with metabolic risk factors for nausea (ie. electrolyte imbalances causing nausea/vomiting)
Patients with mechanical risk factors for nausea (ie. intestinal obstruction)
Patients experiencing nausea and/or vomiting due to use of opioids
Patients with lymphoedematous arms
Patients with chronic alcohol use (chronic alcohol use is associated with minimal levels of nausea and/or vomiting).

3.5.	 Proposed sample size 
In our pilot study15, the mean score for nausea experience averaged over 5 days was 2.79 (weighted average SD 3.15) in the control group and 1.45 (weighted average SD 2.76) in the intervention group.  At least 135 participants per arm would be required to detect this pair wise difference between arms using a t-test with a conservative Bonferroni-adjusted significance level of 0.05/3 = 0.017 at a power of 90%.  The pilot study suggested an attrition rate of 33%, so initially, at least 202 participants would be required per arm. As the standard deviations (SDs) are much larger than the means in the pilot data, they are suggestive of highly skewed distributions; hence the equivalent nonparametric test (the Mann-Whitney test) will be used. As the asymptotic relative efficiency of the Mann-Whitney test is at worst 0.864, the sample size for a Mann-Whitney test is, in the worst case, equal to the sample size for the t-test divided by 0.864.  This would increase the required sample size to 156 per arm before attrition, 233 after attrition, totaling 699 across the three arms.

3.5.1.	Recalculation of sample size requirements during the trial
Due to slower recruitment rate than envisaged initially, it was felt that rethinking of the sample size requirements was necessary. The CTU has analysed the first 141 cases which provided complete data over all four cycles. The Standard Deviation for this cohort of patients was 2.75, slightly lower that the SD of 3 that we included in the initial power calculations. We had also calculated the power of the study to 90%, whereas the standard power in most studies is 80%. We adjusted this number down to 80% power, which is the standard power accepted. With these adjustments in mind, the sample required was at 480 participants. This change was agreed both with the DMEC and the HTA programme.
There were 361 cases with data on the primary outcome (117, 118 and 126 in the three trial arms respectively). Pairwise trial arm comparisons were planned and as the data are skewed a nonparametric test (Mann-Whitney) will be used and this has an asymptotic relative efficiency of at worst 0.864 compared to the t-test. Thus our effective sample sizes are around 117 x 0.864 which is about 100. With such a sample size there is approximately 80% power to detect a standardized difference in means of 0.46 in a two-tail test at the 0.017 level of significance.

Recruitment took  place in the largest single-site cancer centre in the UK, and cancer units or centres of district general hospitals and university hospitals, including the Christie Hospital NHS Trust and its peripheral clinics where chemotherapy is administered (Royal Oldham Hospital, Tameside General Hospital, Leighton Hospital, Stepping Hill Hospital at Stockport, Macclesfield District General Hospital, North Manchester General Hospital),  the Royal Liverpool Hospital, Clatterbridge Centre for Oncology, St Helen’s Hospital and Southport General Infirmary, and three cancer units associated with the University of Plymouth (South Devon Healthcare NHS Foundation Trust, Plymouth Hospitals NHS Trust, Royal Cornwall Hospitals NHS Trust). Available statistics from the Christie Hospital NHS Trust alone had shown that around 9,000 patients receive chemotherapy every year, with approximately two-thirds of these patients receiving chemotherapy in 3-weeks cycles. Recruitment rates were based on a similar antiemetic study we had conducted over four cycles of chemotherapy37, where it had taken us 6 months to recruit 102 patients and retain 65% over the four cycles of chemotherapy. Based on similar recruitment levels at each of the 9 sites listed above, we had estimated that recruitment would be completed in 16 months, with a further 3 months required to complete the follow up of the final patients. Three dedicated researchers and 30 cancer network research nurses recruited patients and collected the data. Data collection was audited regularly and discussed with the Trial Steering Committee and the Data Management and Ethics Committee (DMEC).

3.6.	 Statistical analysis 
Descriptive statistics have been estimated for all baseline socio-demographic and clinical variables by arm, and for outcome variables (scores on nausea and vomiting subscales) by arm. The association between baseline socio-demographic or clinical variables and outcome variables has been assessed using between-group tests or correlations depending on skewness.  Primary outcome variables have been compared between the arms using t-tests, one-way analysis of variance, Mann-Whitney tests and Kruskal-Wallis tests, bearing in mind any skewness in the data.. Ordinal regression models were employed to permit covariate adjusted analyses of a grouped version of the primary outcome. An extension of the proportional odds regression model was used for longitudinal analyses over cycles and this was fitted with a Generalised Estimating Equation (GEE) approach. An intention-to-treat analysis model has been followed. As the primary outcome variable was assessed over several days repeatedly, an aggregate score of all assessments in each cycle was calculated before any modeling analysis.

The effect of missing values was assessed by comparing the numbers and percentages of participants with missing values in the three arms of the study; differences in baseline variables between participants with observed and missing outcomes in each arm; and for participants with observed outcomes, differences in baseline variables between the three arms.  There were no clear associations between known predictors of nausea and cases missing the nausea primary outcome. This fact along with the highly non-normal distribution of the primary response (for which imputation methods are not so well developed) informed our decision to not apply multiple imputation analyses. 

3.7.	 Randomisation method
The trial arm allocation method was minimisation with a random element over the margins of three factors: gender, age (16 to 24, 25 to 50, 51+) and emetogenic risk (low, moderate, high). The first 20 cases were allocated completely at random and thereafter the allocation probability vector was (0.6, 0.3, 0.1) to the arms that would result in the least to the most imbalance respectively. Researchers telephoned the randomisation office staff with the patient details and the staff used an in-house program to obtain the allocated trial arm.

3.8.	 Outcome measures
3.8.1.	Primary outcome:
Rhodes Index of Nausea, Vomiting and Retching49. 
This is an 8-item validated scale measuring nausea and vomiting experience, incidence and severity. In this study, the Nausea experience subscale has been used (as shown in appendix 1) for power calculations of the sample size, using the mean score across all assessment days in each cycle as the end point. From the nausea experience score, incidence and severity can also be isolated. Scores can range from 0-12, with higher scores indicating higher levels of the symptom experience. This scale, taking 1-2 minutes to complete, was done daily from the day before chemotherapy (to capture any anticipatory nausea) up to seven days post chemotherapy i.e. 8 assessments/cycle.
3.8.2.	Secondary outcomes:
MASCC Antiemesis Tool (MAT) 
This is a scale designed by the Multinational Association of Supportive Care in Cancer (MASCC) 39. This 8-item scale assesses in a simple way both acute and delayed nausea and vomiting incidence and extent and was designed specifically for chemotherapy-related nausea and vomiting. This short clinical scale has shown satisfactory internal reliability (a=0.77), contrasted-groups and concurrent validity, and high recall of events up to 3 weeks post chemotherapy. The MASCC Antiemesis Toolis designed to be used once-per-cycle with retrospective patient recall of events, minimising the patient burden. Factor analysis has clearly identified three factors, namely vomiting, acute nausea and delayed nausea39. The scale (see appendix 2) was completed at day 10 of each cycle (=4 assessments).
FACT-G quality of life scale. 
This is a well-validated quality of life scale focusing on functional assessment50. This functional scale has not only provided quality of life indications, but also changes in other symptoms/side effects that may have resulted from any improved management of nausea (ie. appetite). High internal consistency and construct validity have been reported in past studies using the FACT scales in various cancer populations. Completion time is about 5 minutes. This scale (given in appendix 3) was completed at baseline and then at day 10 of each cycle (=5 assessments).
Hospital Anxiety & Depression Scale51. 
This is a 14-item scale assessing anxiety with 7 items and depression with a further 7 items. Each item is answered on a 4-point scale (0-3). Scores on each sub-scale thus range between 0 (no symptoms) and 21 (numerous and severe symptoms). There are separate scores for anxiety and for depression51. In this study, the Anxiety subscale was obtained at baseline (see appendix 4), the score of which was  used as a covariate in the final statistical analysis of the data, as anxiety is a key risk factor for the development of nausea/vomiting29,43. This scale has been used extensively with cancer patients as a screening tool and has been reported to have excellent psychometric properties. Completion time is approximately 2-5 minutes. 
Patient Expectations of Nausea/Vomiting. 
As this is a key risk factor identified in the literature29,43, a 2-item scale was developed assessing the patient expectation for nausea and vomiting, measured on a 10-point ordinal scale . We have used the same measurement approach elsewhere in the past77, although no validation of these 2 items has formally taken place. This was incorporated in the final analysis of outcomes. Patients were also asked how much they believed this method had helped them alleviate nausea and how much faith they had in complementary therapies using 10-point scales (see appendix 5). 
Sociodemographic and treatment characteristics were obtained from the patients’ records and the patients themselves (appendix 6). These included gender, age, educational level, marital status, experience with nausea in the past such as during pregnancy, motion sickness or nausea when eating certain foods, use of/experience with other complementary therapies in the past, cancer diagnosis, stage of disease, and chemotherapy protocol used and dosage. Such a questionnaire had already been developed by the team and used in the past in other nausea/vomiting studies15,29. Medication use (standard and rescue antiemetics) during study participation were obtained from the pharmacy records. Furthermore, although not formally required, researchers were asking patients for any side effects (or patients could volunteer side effect information) and these were recorded in a descriptive manner.
Assessment scales were provided to patients for self-completion at home; completed forms were returned back to researchers using a pre-paid self-addressed envelope (see Table 1). Patients were asked to complete their daily assessments of nausea at the same time in the evening to have a consistent time frame for measuring change. Patients were reminded to return their completed scales when attending for chemotherapy, and were also contacted at an early stage during the trial when the researcher would remind patients of the instructions for completing and returning the scales.

Table 1. Timing of completion of study assessment forms

	Baseline assessment	Chemo days                 -1,0,1,2,3,4,5,6x 4 cycles	Chemo day   10X 4 cycles	End of study participation
Rhodes Index of Nausea and Vomiting		X		
MASCC Antiemesis Tool			X	
FACT-G	X		X	
Hospital Anxiety & Depression Scale	X		X	
Patient Expectations Questionnaire	X			
Sociodemographic variables	X			
Disease/treatment variables	X			X
Health economics assessment	X	X	X	X


3.9.	 Wristband compliance and audit
Patients who had been randomised to the acupressure and sham acupressure groups were also asked to provide information about the length of time that they had worn their wristbands on the day of chemotherapy and the 6 subsequent days. A wristband compliance questionnaire (see appendix 7) per cycle was given to the patients to complete and return in the pre-paid envelope together with the completed scales.
In addition to compliance with wearing wristbands, it was important to determine whether patients were wearing the wristbands correctly according to the instructions they had been given. A wristband audit was conducted at two Manchester sites (Christie NHS Foundation Trust and Macclesfield District Hospital) and two Liverpool sites (Clatterbridge Centre for Oncology and the Royal Liverpool Hospital). Research nurses who were involved with patient recruitment into the trial assessed how correctly patients were wearing their wristbands when they attended for chemotherapy treatment. In total, observations were carried out for 35 pairs of wristbands. An audit proforma is shown in appendix 8.
Due to the device nature of the intervention the trial did not come under MHRA regulations as it was not a clinical trial of an Investigational Medicinal Product as defined by the EU Directive 2001/20/EC. The nature of the intervention therefore did not require a procedure for the reporting of serious adverse events. However, patients were regularly asked about their experiences with regard to wearing wristbands (for example when attending for chemotherapy and during routine telephone communication during the trial), and any comments made regarding any kind of problems associated with the wristbands (for example if a larger size was required; if the wristband caused any kind of discomfort; if the wristband became damaged) were logged by the researchers, with appropriate advice offered to the patient.

3.10.	Measurement of costs
Costs were identified, measured and valued using a micro-costing approach (by which each component of resource use was identified, estimated and a unit cost derived from market prices and national estimates52). The cost analysis was performed from the perspective of the health service provider and from a societal perspective. Included in the health care provider costs were those accrued by the acute trusts and PCTs. Costs to the patients and their families, including social care, were considered as the additional costs for society. Indirect costs in terms of workdays lost were also included. 
Data were collected prospectively and retrospectively using multiple sources including patient records and patient self reported questionnaires (appendix 9 and10). The questionnaires reported health service utilisation subsequent to and as a result of chemotherapy induced nausea/vomiting (e.g. GP visits), patient out of pocket expenses such as over the counter medicines or transport together with use of services in the social sector such as home help and support from family and friends. Valuation of resource items including hospital resources (e.g. bed days and staff time) and community resources (e.g. GP visits, home help) use were carried out using national estimates52; market prices were assigned to medication; non-market items, specifically patient time and informal help provided by family and friends, were valued using market wage rates; out of pocket expenses (e.g. bus fares) used financial expenditures.
In more detail, direct medical costs were defined as those of prophylactic or rescue antiemetic medications, drug administration devices, staff time associated with preparing and administering medication and tending to patients with chemotherapy-induced nausea and vomiting, hospitalizations due to chemotherapy-induced nausea and vomiting, hospital outpatient or GP visits due to chemotherapy-induced nausea and vomiting and costs for over-the-counter medications or other complementary therapies. Direct non-medical costs were those for transportation and need for assistance, such as additional childcare. Indirect costs were based exclusively on the number of workdays lost due to chemotherapy-induced nausea and vomiting. Costs that were not included in this evaluation were costs for chemotherapy agents, preplanned visits or hospitalizations for the purpose of chemotherapy administration, diagnostic and laboratory tests, and other patient management costs not directly related to chemotherapy-induced nausea and vomiting. 
Analysis of Economic Data: The total cost of each arm of the trial was calculated by combining the resource use and unit cost data.  No discounting was necessary given the time period of data collection (less than 1 year); sensitivity analysis was carried out to account for uncertainty where estimates in cost data were used. Differences in costs between the three arms were tested for using independent sample t-tests. Cost data in each of the arms were analysed alongside the quality of life measures with the data combined and analysed using cost effectiveness ratios (i.e. the difference in costs between alternatives relative to the difference in effectiveness between the same alternatives). Cost per quality adjusted life year (QALY) are presented. 


3.11.	Nested Qualitative Study

There was an exploratory nested qualitative study within the trial which explored patients’ reasons for consenting to take part in the trial, and their experiences of participating in a randomised controlled trial for acupressure wristbands.

A number of qualitative studies have explored patients’ experiences of receiving treatment with acupuncture, and their findings have suggested that the treatment is associated with eliciting benefits beyond the alleviation of the patients’ presenting condition53-55. These expanded effects of care include improvements in physical/mental health, emotional well-being and changes in personal identity and lifestyle, and can result in patients ‘feeling normal again’ and ‘regaining their lives.’ Despite the burgeoning qualitative research exploring the experiences of patients receiving acupuncture, to date no study has been conducted to explore the experiences of users of acupressure or acupressure wristbands. To address this gap in the evidence base, a nested qualitative study was conducted with patients taking part in the main trial. 

3.11.1.	Objectives
1.	To outline patients’ experiences of using acupressure wristbands.
2.	To outline the reasons why patients consent to take part in a clinical trial of acupressure wristbands.
3.	To outline patients’ experiences of taking part in a randomised controlled trial of acupressure wristbands.

3.11.2.	Sample
A purposive sample of patients who had taken part in the clinical trial of the effectiveness and cost-effectiveness of acupressure wristbands for chemotherapy-induced nausea and vomiting participated in one-to-one semi-structured interviews. Patients were recruited from each of the three geographical sites, represented all three study arms, had either high or low scores in the item about their expectation of effect from the wristbands and either had or did not have experience using complementary therapies in general. 

3.11.3.	Methodology
Interviews were conducted by three members of the research team and were directed by a topic guide. Topic guides were updated throughout the study to incorporate emerging themes. Interviews were audio-taped and transcribed verbatim. Interviews lasted for between 30 and 70 min. Transcripts were analysed thematically using Framework analysis, a manual, matrix method, which facilitates thematic and cross-case interpretation56,57. Analysis proceeded in five stages:
	Familiarization. Transcripts were read and re-read by members of the research team to familiarize and immerse in the data.
	Identification of the thematic framework. Key issues, concepts and themes arising from the data were identified, and grouped thematically to construct a conceptual framework.
	Indexing. Two of the research team independently applied the thematic framework to the same transcript to explore any differences in application. The thematic framework was then applied systematically to all the data. 
	Charting. Thematic matrices were constructed for all identified categories/subcategories to further summarise and synthesise the indexed data. 
	Detection, categorization and classification. The original research questions were reconsidered, and the charts examined in order to define concepts, map the range and nature of phenomena, find any associations and provide explanations.

3.12.	Research Governance
The sponsor of the study was The University of Manchester. The MHRA has confirmed that this trial does not fall under the clinical trial regulations 2004, as mentioned earlier on.
Trial Steering Committee: A Trial Steering Committee was formed which was chaired by a patient representative. Other members included a medically trained expert in chemotherapy nausea independent of the study, an acupressure practitioner, a representative of the trials unit (statistician), the lead applicant and two of the co-applicants, one of which was the study’s user/co-applicant. This committee was responsible for trial safety and assurance of scientific validity, and was convened four times, once after completion of the preparatory part of the trial, twice more during the recruitment phase and once after data cleaning and before data analysis.
Data Monitoring & Ethics Committee (DMEC): An independent DMEC was set up by the Christie Cancer Trials unit as per standard procedures to review accruing trial data on a regular basis and also to ensure that sufficient patients were enrolled, reporting back to and guiding the trial’s Steering committee, and also reporting to the HTA via the steering committee. The members of this committee were not linked to the study in any way.
Trial Management: The Christie Cancer Clinical Trials Unit was responsible for data management. It is based within the R&D division of the Christie Hospital NHS Foundation Trust. The unit manages international, national and local studies and its portfolio during the conduct of our trial included 3 international studies, 14 randomised studies and 12 other studies. These included a number of studies with funding from CRUK via the CTAAC route. The unit has a strategic alliance with the MRC trials unit in London, and the development and operation of the Christie unit is supported by the MRC unit.
The Trials unit has robust governance and management systems which have been subjected to a MHRA GCP inspection where the inspectors described the systems for the management of clinical trials as ‘robust’. This study was conducted in accordance with the unit’s Standard Operating Procedures; these cover all aspects of the management of clinical trials and the unit can assure funders that the studies supported are managed within a quality framework that has been reviewed by the MHRA. The unit has been responsible for the monitoring of the trial to ensure that it is conducted in accordance with the protocol, research governance framework and applicable regulations. A full list of standard operating procedures is available on request and in the unit’s website. The unit had the capacity and capability to support a trial of this nature (indeed it has in its portfolio another national study on complementary therapies using acupuncture) and was able to identify a project lead to oversee the work of the data manager. The data manager was responsible for ensuring that the data generated by the study was reviewed appropriately by the DMEC and the trials supported by the unit are typically reviewed through these mechanisms. Randomisation and statistical analysis have been supported by the unit’s statisticians.

3.13.	Service user involvement
Service users were involved at 3 levels. The first has been at the development phase of this proposal, with the contribution of the Chair of the NCRI Consumer Liaison group, who was a named co-applicant in the study, and reviews by expert patients. The second level was monitoring the trial project and guiding it within its scientific framework through chairing and participating in the trial’s Steering committee and the DMEC. Finally, users have advised us in planning appropriate patient-focused dissemination of the trial results at the end of the study. For reviews, contacts, active involvement and access, the research partners’ strategy and mechanisms through the NCRI Cancer Experiences Collaborative have been utilised.


4.	MAIN FINDINGS

4.1. Patient Recruitment

Three study centres were involved in patient recruitment, namely Manchester, Liverpool and Plymouth. Recruitment began with a month long pilot phase in Manchester at The Christie hospital to test recruitment processes. The first case was randomised on 23March 2009 and the last case on 15 October 2010. A phased recruitment launch followed in the two remaining centres with patient recruitment starting in Liverpool in May 2009, and in Plymouth in June 2009. 500 cases were randomised (166 Standard care [None], 166 Sham acupressure [Sham] and 168 Acupressure [Acu] groups).  In total 14 hospital sites were involved in recruitment as shown in Table 2 below:

Table 2: Trial recruitment per study site

Main centre and total number of patients recruited	Breakdown of recruitment per study site
Manchester (244 patients randomised over 76 weeks)	119 from Christie Hospital (including initial pilot phase)50 from Royal Oldham Hospital1 from Tameside General Hospital5 from Leighton Hospital39 from Stepping Hill Hospital26 from Macclesfield District General4 from North Manchester General Hospital
Liverpool (161 patients randomised over 71 weeks)	33 from Clatterbridge Centre for Oncology79 from Royal Liverpool Hospital41 from St Helen’s Hospital8 from Southport General Infirmary
Plymouth (95 patients randomised over 64 weeks)	2 from Torbay District General Hospital88 from Derriford Hospital5 from Royal Cornwall Hospital


Monthly recruitment for the trial is given in figure 1 below:

Figure 1: Trial recruitment by month

Note:  Monthly target accrual was recalculated after sample size adjustment in May 2010, with the agreement of the HTA team. Power was initially calculated to 90%, but as recruitment was slower than expected the sample size was recalculated to 80% power.

A participant flow diagram (figure 2; CONSORT diagram) shows the numbers of participants recruited and randomly assigned to the three trial arms and who received the intended interventions and were analysed for the primary outcome.



Figure 2: Patient recruitment into the ANCHoR Trial: Manchester, Liverpool and Plymouth Sites, March 2009-October 2010

											500 patients consentedto ANCHoR											
																						
		168 randomised to acupressure group(11 withdrawn / died*)						166 randomised to no wrist bands group (15 withdrawn / died**)						166 randomised to sham acupressure group(10 withdrawn / died***)		
																						
36 lost to follow up(no outcome data)(6 withdrawn / died)		132 patients retained in trial		45 lost to follow up(no outcome data)(7 withdrawn / died)		121 patients retained in trial		47 lost to follow up(no outcome data)(7 withdrawn)		119 patients retained in trial
																						
				50 patients, partial data1(5 with-drawn)		82 patients, complete data						41 patients, partial data1(8 with-drawn / died)		80 patients, completedata						43 patients, partial data1(3 with-drawn)		76 patients, complete data

*	eyesight problems: 1	**	chemotherapy changed: 1	***	difficulties with chemotherapy: 1
	felt very ill: 1		chemotherapy stopped: 2		chemotherapy stopped: 1
	lymphoedema: 1		didn’t receive wristbands: 4		ineligible re. screening criteria: 4
	sore arms after chemotherapy: 1		felt very ill: 2		sore arms after chemotherapy: 2
	uncomfortable wristbands: 2		no reason given: 3		uncomfortable wristbands: 1
	unhappy with questionnaires: 1		died:	3		no reason given: 1
	no reason given: 2				
	died: 2		Please note: Data represented in this figure include pilot phase, March-April 2009

1Partial data indicates data collected from less than the complete dataset (baseline plus 4 cycles of chemotherapy), ie. where at least 1 assessment was missing

4.2. Descriptive statistics by trial arm
The majority of the participants were females, married and older than 50 years old. The key diagnoses of the sample included breast and colorectal cancer and the majority had received moderately emetogenic chemotherapy (including anthracycline-based chemotherapy). Other sociodemographic can clinical data can be seen in Table 3.

Table 3. Demographic and clinical data of the sample
Gender	None	Sham bands	Acu bands
Male	38	37	39
Female	128	129	129
Age group (years)			
Younger or equal to 50	51	55	54
51+	115	111	114
Marital status			
Single	18	15	24
Married	85	83	88
Divorced or separated	20	27	21
Widowed	13	16	11
Missing	30	25	24
Educational attainment			
Primary school	0	3	2
Secondary school	68	74	69
College/Diploma	37	26	43
University/Degree	20	14	17
Postgraduate	6	12	8
Missing	35	37	29
Ethnic origin			
Caucasian	111	110	121
Black	0	1	2
Asian/Chinese	2	2	2
Mixed	1	3	0
Missing	52	50	43
Religious affiliation			
Christian	114	106	122
Muslim	1	2	3
Hindu	0	1	0
None	17	18	12
Prefers not to say	1	4	2
Other	5	8	7
Missing	28	27	22
Occupational group			
Professional	40	44	36
Managerial & technical	17	16	23
Skilled non manual	14	11	16
Skilled manual	14	12	11
Unskilled	14	16	15
Not applicable	28	33	43
Missing	39	34	24
Occupational status Office of Population Censuses and Surveys			
Employed full-time	50	36	33
Employed part-time	22	17	26
Retired	46	50	51
Unemployed	2	4	3
Casual worker	0	0	1
Not working due to ill health	10	20	17
Housewife	5	11	10
Other	2	3	4
Missing	29	25	23
Smoking history			
Never	63	62	66
Previously	56	51	62
Current	20	25	18
Missing	27	28	22
Diagnosis			
Breast	89	90	82
Bowel (colon & rectum)	25	27	19
Gynaecological	20	15	21
Lung	7	10	21
Lymphoma	6	2	7
Oesophagus	4	5	2
Stomach	2	3	1
Pancreas	1	1	4
Melanoma	2	2	1
Bladder	1	1	2
Gall bladder	0	1	1
Head & neck	1	1	0
Endocrine/thymus	0	1	1
Prostate	1	0	1
Child: Ewing’s sarcoma	1	1	0
Child: Non-Hodgkin’s lymphoma	0	1	0
Missing	6	5	5
Emetogenic risk			
Low	13	11	12
Moderate	107	111	111
High	46	44	45

4.3. Assessment of missing data for the primary outcome

500 cases were randomised but there is only data for 361 of these for the primary outcome i.e. around 28% of cases are missing the primary outcome. The following Table 4 illustrates the proportion of cases missing the primary outcome by various factors thought to influence nausea propensity for the remaining 497 cases.

Table 4. The proportion of cases missing the primary outcome by trial arm

Factor	Level	Missing primary outcome	p-value*
Trial arm	None	46/163 (28%)**	0.69
	Sham	48/166 (29%)	
	Acu	42/168 (25%)	
Age	<=50	42/160 (26%)	0.78
	51+	94/337 (28%)	
Gender	Male	35/114 (31%)	0.43
	Female	101/383 (26%)	
Emetogenic risk	Low	12/36 (33%)	0.69
	Moderate	87/327 (27%)	
	High	37/134 (28%)	
2 weekly CT	No	122/451 (27%)	0.75
	Yes	14/46 (30%)	
Baseline anxiety	Normal (0-7)	50/250 (20%)	0.16
(83 missing)	Borderline (8-10)	22/76 (29%)	
	Case (11-21)	24/88 (27%)	
Nausea expectation	0-3	24/100 (24%)	0.80
(84 missing)	4-6	52/224 (23%)	
	7-10	18/89 (20%)	
* Chi-square tests of equal proportions.
** Three were all allocated to “No acupressure” but there are no records in the trial database for these 3 cases i.e. no completed screening forms and no returned data forms. These 3 cases are the discrepant ones between n=500 and n=497.

There are no marked associations of any of these factors with the probability of missing the primary outcome.

Inevitably there is further dropout of cases with each cycle as illustrated in the following Table 5:

Table 5. Dropout data by trial arm over the four cycles of chemotherapy

Dropout status	None	Sham	Acu	Total
Immediate (no outcome data)	45	47	36	128
Complete (all outcome data)	80	76	82	238
Cycle 1 then dropped out	12	14	14	40
Cycle 1-2 then dropped out	11	17	12	40
Cycle 1-3 then dropped out	14	11	12	37
Intermittent data	4	1	12	17
Total	166	166	168	500


Table 6 below shows the mean nausea experience of the patients using the Index of Nausea, Vomiting and Retching scale. Scores can be from 0-12, with higher scores indicating higher levels of nausea. Both the sham and acupressure arms had less nausea experience compared to the standard care arm, although this did not reach statistical significance. To note that these mean values represent very low levels of nausea. Only at cycle 4 results become significant (P<0.05) with the acupressure group having no nausea experience reported.

Table 6. Mean Rhodes nausea experience (days 0-6). Entries are median (min, lower quartile, upper quartile, max):

Cycle	None	Sham	Acu
1	1.43 (0, 0, 3.71, 8.57)N=117	0.57 (0, 0, 2.64, 9.17)N=118	(0, 0, 2.97, 7.50)N=126
2	1.71 (0, 0, 3.43, 10.14)N=109	0.71 (0, 0, 2.14, 10.29)N=105	0.93 (0, 0, 3.43, 9.57)N=114
3	1.14 (0, 0, 3.86, 11.86)N=96	0.71 (0, 0, 2.29, 9.71)N=88	0.43 (0, 0, 3.00, 10.14)N=103
4	1.14 (0, 0, 4.00, 9.14)N=81	0.43 (0, 0, 2.43, 8.57)N=77	0.00 (0, 0, 1.82, 9.86)N=90



Tables 7 and 8 show frequencies of the nausea and vomiting experience respectively, categorised over five groups of experience.

Table 7. Number of participants in each nausea experience score (based on Rhodes nausea experience subscale, days 0-6):


Cycle 1
	0	(0-2]	(2,4]	(4,6]	>6	<NA>
None	34	35	21	14	13	49
Sham	36	47	19	8	8	48
Acupressure	41	38	28	11	8	42
Cycle 2
None	32	29	27	9	12	57
Sham	36	41	13	10	5	61
Acupressure	43	29	19	10	13	54
Cycle 3
None	33	22	19	14	8	70
Sham	33	31	10	9	5	78
Acupressure	43	29	11	8	12	65
Cycle 4
None	27	23	13	10	8	85
Sham	36	16	15	7	3	89
Acupressure	53	17	8	6	6	78





Table 8. Number of participants in each vomiting experience score (based on Rhodes vomiting experience subscale, days 0-6):

Cycle 1
	0	(0-1]	(1,2]	(2,3]	>3	<NA>
None	76	24	11	4	3	48
Sham	80	27	7	3	1	48
Acupressure	85	24	9	7	1	42
Cycle 2
None	74	20	9	2	3	58
Sham	74	21	6	4	0	61
Acupressure	90	16	2	4	2	54
Cycle 3
None	75	13	3	0	5	70
Sham	68	15	4	0	1	78
Acupressure	81	15	3	1	3	65
Cycle 4
None	60	11	3	5	2	85
Sham	61	12	1	2	1	89
Acupressure	76	9	3	1	1	78



Tables 9 and 10 below present descriptive data of acute and delayed nausea based on the MASCC Antiemesis Tool scale, showing similar results with the Index of Nausea, Vomiting and Retching scale. Tables 11 and 12 report the same for acute and delayed vomiting based on the MASCC Antiemesis Tool scale.
Table 9. MASCC Antiemesis Tool- acute nausea: Number of participants reporting a score from ‘0’ to ‘10’

Cycle 1
	0	1-3	4-6	7-9	10	<NA>
None	63	20	14	11	9	49
Sham	65	33	9	8	5	46
Acupressure	72	29	14	8	7	38
Cycle 2
None	56	28	14	6	6	56
Sham	71	21	4	8	2	60
Acupressure	68	25	7	8	8	52
Cycle 3
None	52	24	10	7	3	70
Sham	53	21	9	4	2	77
Acupressure	65	15	10	8	4	66
Cycle 4
None	44	17	10	7	3	85
Sham	49	16	8	5	1	87
Acupressure	61	12	8	4	3	80



Table 10. MASCC Antiemesis Tool- delayed nausea: Number of participants reporting a score from ‘0’ to ‘10’


Cycle 1
	0	1-3	4-6	7-9	10	<NA>
None	49	24	21	13	11	48
Sham	61	25	14	7	9	50
Acupressure	58	30	25	8	7	40
Cycle 2
None	43	23	22	11	6	61
Sham	54	24	17	7	2	62
Acupressure	57	28	17	9	5	52
Cycle 3
None	43	22	15	8	5	73
Sham	42	26	14	4	3	77
Acupressure	56	19	13	10	4	66
Cycle 4
None	35	20	10	8	6	87
Sham	44	16	13	4	1	88
Acupressure	57	14	6	7	2	82



Table 11. MASCC Antiemesis Tool- acute vomiting (Number of participants and occasions of vomiting):

Cycle 1
	0	1-3	4-6	7-9	10	<NA>
None	99	10	4	2	2	49
Sham	106	12	1	1	1	45
Acupressure	110	11	5	1	3	38
Cycle 2
None	97	8	1	4	0	56
Sham	94	7	4	1	0	60
Acupressure	101	9	2	0	3	53
Cycle 3
None	91	3	1	1	1	69
Sham	81	5	1	1	0	60
Acupressure	91	8	3	0	0	66
Cycle 4
None	75	4	1	1	0	85
Sham	72	6	0	1	0	87
Acupressure	86	3	0	1	0	78




Table 12. MASCC Antiemesis Tool- delayed vomiting (Number of participants and days of vomiting experience):


Cycle 1
	0	1	2	3	4	<NA>
None	99	9	6	2	3	47
Sham	103	7	3	2	2	49
Acupressure	108	8	7	2	3	40
Cycle 2
None	94	7	3	0	2	60
Sham	98	3	2	1	1	61
Acupressure	104	7	3	0	2	52
Cycle 3
None	86	2	2	1	2	73
Sham	80	5	2	1	1	77
Acupressure	90	6	2	2	1	67
Cycle 4
None	71	2	2	2	3	86
Sham	71	3	2	2	0	88
Acupressure	80	4	1	1	0	82





4.4. Primary outcome analysis

The primary outcome is the mean Rhodes (Index of Nausea, Vomiting and Retching scale) nausea experience (days 0 to 6) for cycle 1. As can be seen from figure 3 the data are highly skewed. The possible range for values is 0 to 12 but in fact 111/361 (31%) are exactly zero and around half of all values are less than 1. No transformation would be successful in normalising such a distribution. 


Figure 3. Primary outcome distribution (n=361)
Note: The intervals are [0,1], (1,2], (2,3], ..[11,12]. The first interval is closed at both ends and subsequent intervals are open at their lower bound and closed at their upper bound


The distribution by trial arm is shown in figure 4. Due to the highly skewed distribution the non-parametric Kruskal-Wallis test has been used for the primary comparison of the trial arms. This overall test is non-significant (p=0.14).

Provision for pairwise comparisons (Mann-Whitney U tests) with a Bonferroni adjustment was made in the trial design: None v Acupressure (p=0.23), None v Sham acupressure (p=0.05), Sham v Acupressure (p=0.40). It should be noted that the reference value for statistical significance is 0.017 and so none of these pairwise comparisons are statistically significant.

Figure 4. Box and whisker plot of the primary outcome by trial arm



4.5. Regression analyses for the nausea primary outcome data

As noted previously the data are highly skewed and no transformation will be successful in normalising the distribution. The approach adopted here is to group the values into five ordered categories and to utilize regression methods for ordinal data. The categories were chosen after inspection of figure 3. The first category “Zero” was chosen as it represented no nausea at all and there was a large fraction of cases that fell into such a category (31%). The choice of the other categories was somewhat arbitrary. Five categories is fairly typical for ordinal regression models in the literature and it is desirable that no category has a very small frequency. Category five has a broad range but only 8% cases; subdividing it further would be counter-productive. Having chosen the lowest and highest categories the remaining three were simply selected to have equal width. The following Table 13 shows the categories and the frequencies by trial arm (n=361).

Table 13. Ordered categories of Nausea experience by trial arm (Number of participants in each group of nausea scores)

Category	Nausea score	None	Sham	Acu
1	0	34	36	41
2	(0, 2]	35	47	38
3	(2, 4]	21	19	28
4	(4, 6]	14	8	11
5	(6, 12]	13	8	8
 

The main tool used was the proportional odds regression model.58

  

	k = 1, 2, 3, 4 denotes category
	i = 1, 2, …, n denotes case
	 is the response category for the i’th case
	 is a vector of covariate values for the i’th case (including trial arm) 
	 is an intercept term for the k’th category
	 is a vector of parameters to be estimated
	Logit(p)  =  log[p/(1-p)]

4.5.1. Unadjusted fit

The following snippet of output in Box 1 is for an unadjusted fit using all the available data (n=361).

Box 1. Unadjusted fit model for nausea experience

Coefficients:
          		          Definition			Value 		Std. Error 	t value
ArmSham           	(Sham=1, otherwise=0)		0.3354     	0.2356   	1.424
ArmAcupressure   	(Acu=1,  otherwise=0)		0.2418     	0.2334   	1.036

Intercepts:
    		Value   		Std. Error 	t value
1|2 		-1.0138  	0.1836    	-5.5203
2|3  		0.3777  		0.1775     	2.1281
3|4  		1.3821  		0.1943     	7.1138
4|5  		2.2506  		0.2343     	9.6047

Residual Deviance: 1055.186 
AIC: 1067.186 

The above data show that:
	The likelihood ratio test of the proportional odds assumption is non-significant (p=0.51) meaning there is no good evidence against this assumption.
	The likelihood ratio test for the trial arm effects is non-significant (p=0.34). 
	The estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control are e0.2418 = 1.27 , 95% CI (0.80, 2.03)
	The estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control are e0.3354 = 1.40 , 95% CI (0.87, 2.24)
Hence, patients in the acupressure arm are 27% more likely to have less nausea/vomiting than the control arm and the sham arm 40%.

4.5.2. Adjusted fit (age, gender and emetogenic risk)

The following snippet of output presented in Box 2 is for an adjusted fit using all the available data (n=361).


Box 2. Adjusted fit model for gender, age and emetogenic level in relation to nausea experience
Coefficients:
                         			Value Std. 	Error 		t value
ArmSham                 		0.3520    	0.2400  	1.4670
ArmAcu                  		0.1689     	0.2368  		0.7131
Age51Plus               		0.7445     	0.2141  		3.4766
GenderMale              		0.7554     	0.2692  		2.8060
EmetogenicRiskLow 		1.3783    	0.4918  		2.8025
EmetogenicRiskModerate 	0.3369     	0.2164  		1.5572

Intercepts:
    Value   Std. Error t value
1|2 -2.0399  0.2793    -7.3029
2|3 -0.4924  0.2579    -1.9094
3|4  0.5786  0.2627     2.2021
4|5  1.4753  0.2909     5.0720

Residual Deviance: 1006.691 
AIC: 1026.691

Table 14 shows the results of the regression analysis assessing variables that affect the primary outcome of nausea. It indicates that, irrespective of arm allocation, subjects that were older than 50 years old and male had better nausea outcome. Also, the emetogenicity of the drug was also significant factor to the nausea outcome.

Table 14. Regression analysis: variables influencing primary outcome (4-variables model)
Term	df	P-value
Arm	2	0.34
Age >= 51	1	0.0005
Male	1	0.005
Emetogenic risk group	2	0.013

The above data show that:
	The likelihood ratio test of the proportional odds assumption is non-significant (p=0.66) meaning there is no good evidence against this assumption.
	The likelihood ratio test for the trial arm effects after adjustment for age group, gender and emetogenic risk group is non-significant (p=0.34). 
	The estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control (for identical age group, gender and emetogenic risk group) is e0.1689 = 1.18 , 95% CI (0.74, 1.90)
The estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control (for identical age group, gender and emetogenic risk group) is e0.3520 = 1.42 , 95% CI (0.88, 2.30).Hence, considering the three risk factors presented in Table 14 and the adjusted data presented earlier, patients in the acupressure arm are 18% more likely to have less nausea/vomiting than the control arm and the sham arm 42%.

It is of interest to consider the impact of adding a trial arm x term interaction effect to the fitted model for each of age group, gender and emetogenic risk group in turn. A regression analysis presents the findings of this impact (Table 15).

Table 15. Regression analysis: trial arm x term interaction effect

Interaction term	df	P-value
Arm x (Age >= 51)	2	0.70
Arm x Male	2	0.002
Arm x (Emetogenic risk group)	4	0.88

This is indicating that there is evidence to suggest that treatment effects may vary with gender. This merits further investigation (see simple illustration later on).

4.5.3. Adjusted fit (age, gender, emetogenic risk, cycle frequency, anxiety and nausea expectation)

There were further values missing for the baseline Hospital Anxiety & Depression Scale- anxiety score and the patient’s pre treatment nausea expectation score. Hence the following snippet of output presented in Box 3 is for an adjusted fit using all the available data (n=315).

Box 3. Adjusted fit model for age, gender, emetogenic level, timing of delivery of chemotherapy, anxiety and nausea expectation in relation to nausea experience
Coefficients:
                          			Value Std. 	Error 		t value
ArmSham                	 	0.26417    	0.25973  	1.0171
ArmAcu                  		0.12936    	0.25220  	0.5129
Age51Plus               		0.51111    	0.22929  	2.2291
GenderMale              		0.67565    	0.32595  	2.0729
EmetogenicRiskLow       	1.23203   	 0.56228  	2.1911
EmetogenicRiskModerate  	0.29651 	0.23076  	1.2849
TwoWeekly              		-0.06794    	0.41474 	-0.1638
Anxiety                		-0.03628    	0.02613 	-1.3887
NauseaExpectation     	 	-0.15455    	0.05046 	-3.0627

Intercepts:
    Value   Std. Error t value
1|2 -0.8360  0.3876    -2.1567
2|3  0.7305  0.3872     1.8868
3|4  1.8205  0.4011     4.5389
4|5  2.8123  0.4293     6.5504

Residual Deviance: 868.2679 
AIC: 894.2679

A regression analysis, presented in Table 16, shows that age >50 years old, male gender, and lower expectation of nausea are significantly linked with lower levels of nausea. The role of the emetogenicity of the chemotherapy in this analysis was borderline non-significant. 

Table 16. Regression analysis: variables influencing primary outcome

Interaction term	df	P-value
Arm	2	0.60
Age >= 51	1	0.025
Male	1	0.038
Emetogenic risk group	2	0.067
2 weekly	1	0.87
Anxiety	1	0.16
Nausea expectation	1	0.002

The above data show that:
	The likelihood ratio test of the proportional odds assumption is non-significant (p=0.31) meaning there is no good evidence against this assumption.
	The likelihood ratio test for the trial arm effects after adjustment for age group, gender, emetogenic risk group, cycle frequency, anxiety and nausea expectation is non-significant (p=0.60). 
	The estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control (for identical values of the other covariates in the model) is e0.1294 = 1.14 , 95% CI (0.69, 1.88)
	The estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control (for identical values of the other covariates in the model) is e0.2642 = 1.30 , 95% CI (0.77, 2.19)
Hence, considering the risk factors presented in Table 16 and the adjusted data presented earlier in this section, patients in the acupressure arm are 14% more likely to have less nausea/vomiting than the control arm and the sham arm 30%.

It is of interest to consider the impact of adding a trial arm x term interaction effect to the fitted model for each of age group, gender, emetogenic risk group, cycle frequency, anxiety and nausea expectation in turn. The results of this analysis are presented in Table 17 and show that only gender (with anxiety being borderline non-significant variable) is significantly linked with the primary outcome. Once again indicating that there is some evidence to suggest that treatment effects may vary with gender. This merits further investigation (see simple illustration later on).


Table 17. Regression analysis: trial arm x term interaction effect (6-variables model)

Interaction term	df	P-value
Arm x (Age >= 51)	2	0.78
Arm x Male	2	0.023
Arm x (Emetogenic risk group)	4	0.93
Arm x (2 weekly)	2	0.14
Arm x Anxiety	2	0.08
Arm x (Nausea expectation)	2	0.16



4.6. Simple illustration of primary outcome by trial arm and gender

The regression analyses above suggest that there may be a trial arm x gender interaction. To illustrate this we may return to the box and whisker plots by trial arm further broken down by gender as shown in figures 5 and 6. Given that we have seen a statistically significant interaction in the ordinal regression analyses there is some justification to repeat the Kruskal-Wallis tests separately within the two gender strata. This yields significant results for males (p=0.04, n=79) and for females (p=0.01, n=282). Descriptively the difference appears to be with the sham arm having a beneficial effect for females but a detrimental effect for males. This is a post-hoc analysis and should be interpreted with due caution especially as there are a limited number of males.

Figure 5. Box and whisker plot of the primary outcome by trial arm for males


Figure 6. Box and whisker plot of the primary outcome by trial arm for females


4.7. Longitudinal regression analyses of mean Rhodes nausea experience scores

The mean Rhodes nausea experience (days 0 to 6) have also been calculated for cycles 2, 3 and 4. Once again the scores for each cycle have been grouped in the same manner as previously to a five point ordinal scale. Thes repeated ordinal data have been analysed using an extension of the proportional odds regression model described previously this time fitted using a Generalised Estimating Equation (GEE) approach59. A working autoregressive correlation structure has been assumed but the regression parameters are robust to this assumption. All reported Wald tests have used the robust covariance estimates.


4.7.1. Unadjusted fit

First a trial arm by cycle model was fitted and the interaction term was tested for significance (Wald test chi-square on 6 df, p=0.25). There being no formal evidence for different treatment effects with cycle, the simpler trial arm + cycle model was fitted as presented in Box 4.

Box 4. Interaction effects in a model of trial arm by cycle  
Coefficients:
                  	Estimate  Naive S.E.  	Naive z  	Robust S.E.  	Robust z
Intercept 1|2      -0.9794     0.1399   	-6.9980      	0.1613     	-6.069
Intercept 2|3       0.2440     0.1357    	1.7972      	0.1567      	1.557
Intercept 3|4       1.1257     0.1439    	7.8185      	0.1628      	6.910
Intercept 4|5       1.9900     0.1675   	11.8760      	0.1876     	10.607
Sham                	0.3823     0.1603    	2.3851      	0.1977      	1.933
Acu                 	0.4255     0.1563    	2.7225      	0.2023      	2.103
Cycle2              	0.0406     0.1124    	0.3609      	0.0899      	0.451
Cycle3              	0.1680     0.1341    	1.2530      	0.0973      	1.725
Cycle4              	0.4708     0.1472    	3.1984      	0.1199      	3.925

	The score test of the proportional odds assumption is non-significant (p=0.27) meaning there is no good evidence against this assumption.
	The estimated correlation parameter (95% CI): 0.345  ( 0.001 ,  0.997 ) i.e. mild autocorrelation with a very wide confidence interval.
	The Wald test for the trial arm effects on 2 df is of borderline significance (p=0.07). 
	The estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control is e0.4255 = 1.53 , (1.12, 2.09)
	The estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control is e0.3823 = 1.47 , (1.06, 2.02)
	The Generalised Estimating Equation approach is valid with an ignorable missing response mechanism (MCAR: Missing Completely At Random). All results should be interpreted with this in mind and sensitivity analyses with respect to missing data mechanisms will be performed. 


4.7.2. Trial arm effects by gender from adjusted regression analyses

The regression analyses described previously for the cycle 1 nausea primary outcome revealed a trial arm x gender interaction. A parallel longitudinal analysis also displayed the same interaction (data not shown). A useful summary of the trial arm effects is given below in Tables 19 (cycle 1) and 20 (cycle averaged data). The odds ratio terms are the ratio of the odds of a lower (i.e. better) nausea score for each of categories 1 to 4 in the 5 point ordinal scale described previously.

Table 19. Odds ratio and confidence intervals for nausea experience in Cycle 1 

Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.35	(0.12, 1.03)
Sham to None (Females)	2.02	(1.19, 3.42)
Acu to None (Males)	1.27	(0.40, 4.08)
Acu to None (Females)	1.17	(0.70, 1.95)
 
* From a proportional odds model adjusting for gender, age group and emetogenic risk group.

Table 20. Odds ratio and confidence intervals for nausea experience- Longitudinal outcomes (i.e. cycle averaged effects)

Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.66	(0.29, 1.48)
Sham to None (Females)	1.71	(1.10, 2.65)
Acu to None (Males)	1.47	(0.59, 3.68)
Acu to None (Females)	1.44	(0.93, 2.23)
 
* From a proportional odds model (Generalised Estimating Equation fit) adjusting for gender, age group, emetogenic risk group and cycle.

From these estimates and confidence intervals we see that there was a statistically significant benefit for females in the sham arm (but not for males where the effect was in fact reversed). Both males and females appear to have enjoyed a benefit of similar magnitude in the Acupressure arm but this is not formally statistically significant. The same caveats as mentioned previously apply i.e. post-hoc analyses, relatively small number of males and assumptions about missing data mechanism.

4.8. Longitudinal analyses of secondary outcomes

4.8.1. MASCC Antiemesis Tool: acute and delayed nausea

These were both scored 0-10 and were highly skewed with large proportions on the 0 extreme. For regression analysis new ordered factors with 5 levels were created as follows:

Group	Score
None	0
Mild	1-3
Mod	4-6
High	7-9
Severe	10

The regression analyses followed a similar approach to that employed for the Rhodes nausea experience described earlier. For both outcomes there was no evidence of an arm x cycle interaction but both outcomes exhibited evidence of an arm x gender interaction. The following Tables 21 and 22 show the arm effect estimates:


Table 21. Longitudinal outcomes (i.e. cycle averaged effects for MASCC Antiemesis Tool acute nausea)

Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.32	(0.12, 0.82)
Sham to None (Females)	1.62	(1.04, 2.53)
Acu to None (Males)	0.63	(0.21, 1.96)
Acu to None (Females)	1.27	(0.82, 1.96)
 
* From a proportional odds model (Generalised Estimating Equation fit) adjusting for gender, age group, emetogenic risk group and cycle.


Table 22. Longitudinal outcomes (i.e. cycle averaged effects for MASCC Antiemesis Tool- delayed nausea)

Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.54	(0.21, 1.40)
Sham to None (Females)	1.74	(1.12, 2.68)
Acu to None (Males)	0.99	(0.37, 2.69)
Acu to None (Females)	1.49	(0.97, 2.28)
 
* From a proportional odds model (Generalised Estimating Equation fit) adjusting for gender, age group, emetogenic risk group and cycle.


4.8.2. MASCC Antiemesis Tool- acute and delayed Vomiting

The mean (days 0-6) Rhodes vomiting experience data was highly skewed. These were grouped 0, (0,1], (1,2], (2,3] and >3. When analysed with a longitudinal proportional odds model there was no evidence of any trial arm effects (p=0.47, Wald test).

The MASCC Antiemesis Tool- acute vomiting data was recorded as the number of times in the 24 hours since chemotherapy. Descriptively there was no difference between the trial arms. The MASCC Antiemesis Tool-delayed vomiting was recorded as the number of days on which vomiting occurred 0-4. When analysed with a longitudinal proportional odds model there was no evidence of any trial arm effects (p=0.69, Wald test).

4.8.3. Longitudinal analyses for nausea and vomiting using post hoc dichotomies

In previous analyses these outcomes were mapped to a 5 point ordinal scale and proportional odds models were fitted. In each case a test of the proportional odds assumption was made and found to be non-significant. Essentially that implies that the odds of a lower score for a variable (notably trial arm) does not depend on the particular cut point. Most cases have low scores for nausea and vomiting and it is felt that a simple dichotomy may give an adequate simpler description (see Tables 23-28 using both the Index of Nausea, Vomiting and Retching scale and MASCC Antiemesis Tool scales). Longitudinal binomial models were fitted (cycle+arm using Generalised Estimating Equation) with a general working correlation structure and a Wald test employed using the robust covariance estimates to assess the trial arm effects. The reason for the dichotomies stated above is that the models for ordinal data typically consider the cumulative logits (CL); that is to say the log odds of a lower score. With the five categories used for the nausea outcome we consider four such cumulative logits evaluated at the category upper limits: 

CL(y) = log[Prob(Y ≤ y) / Prob(Y>y)]  y = 0, 2, 4, 6

In a regression context we aim to see how covariates affect these cumulative logits. In an unconstrained model there would be a term for each covariate for each of the four response categories. Nausea experience and vomiting experience are each scored 0-12 whereas MAT scores are scored 0-10. All of these distributions are markedly skewed with those for vomiting being even more skewed than those for nausea. Five categories were selected for each but the definitions of these were permitted to vary from variable to variable. As the proportional odds assumption was not violated for each variable, the results should not be too sensitive to the particular dichotomy used.


Table 23. Frequency of nausea per trial arm: Rhodes nausea experience (days 0-6) = 0-2 inclusive

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	69/117 (59%)	61/109 (56%)	55/96 (57%)	50/81 (62%)
Sham	83/118 (70%)	77/105 (73%)	64/88 (73%)	52/74 (70%)
Acu	79/126 (63%)	72/114 (63%)	72/103 (70%)	70/90 (78%)

The Wald test for the arm effects gave p=0.08 with odds ratios of the lower score being estimated as 1.62 for Sham and 1.46 for Acupressure when compared to None.


Table 24. Frequency of vomiting per trial arm:  Rhodes vomiting experience (days 0-6) = 0-1 inclusive

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	100/118 (85%)	94/108 (87%)	88/96 (92%)	71/81 (88%)
Sham	107/119 (90%)	95/105 (90%)	83/88 (94%)	73/77 (95%)
Acu	109/126 (87%)	106/114 (93%)	96/103 (93%)	85/90 (94%)

The Wald test for the arm effects gave p=0.19 with odds ratios of the lower score being estimated as 1.74 for Sham and 1.46 for Acupressure when compared to None.


Table 25. MASCC Antiemesis Tool- acute nausea frequency per trial arm= 0-3 inclusive

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	83/117 (71%)	84/110 (76%)	76/96 (79%)	61/81 (75%)
Sham	98/120 (82%)	92/106 (87%)	74/89 (83%)	65/79 (82%)
Acu	101/130 (78%)	93/116 (80%)	80/102 (78%)	73/88 (83%)

The Wald test for the arm effects gave p=0.18 with odds ratios of the lower score being estimated as 1.60 for Sham and 1.29 for Acupressure when compared to None.

Table 26. MASCC Antiemesis Tool- delayed nausea frequency per trial arm= 0-3 inclusive

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	73/118 (62%)	66/105 (63%)	65/93 (70%)	55/79 (70%)
Sham	86/116 (74%)	78/105 (74%)	68/89 (76%)	60/78 (77%)
Acu	88/128 (69%)	85/116 (73%)	75/102 (74%)	71/86 (83%)

The Wald test for the arm effects gave p=0.13 with odds ratios of the lower score being estimated as 1.51 for Sham and 1.43 for Acupressure when compared to None.


Table 27. MASCC Antiemesis Tool- acute vomiting frequency per trial arm= 0

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	99/117 (85%)	97/110 (88%)	91/97 (94%)	75/81 (93%)
Sham	106/121 (88%)	94/106 (89%)	81/88 (92%)	72/79 (91%)
Acu	110/130 (85%)	101/115 (88%)	91/102 (89%)	86/90 (96%)

The Wald test for the arm effects gave p=0.98 with odds ratios of the lower score being estimated as 1.05 for Sham and 1.00 for Acupressure when compared to None.


Table 28. MASCC Antiemesis Tool- delayed vomiting frequency per trial arm= 0

	Cycle 1	Cycle 2	Cycle 3	Cycle 4
None	99/119 (83%)	94/106 (89%)	86/93 (92%)	71/80 (89%)
Sham	103/117 (88%)	98/105 (93%)	80/89 (90%)	71/78 (91%)
Acu	108/128 (84%)	104/116 (90%)	90/101 (89%)	80/86 (93%)

The Wald test for the arm effects gave p=0.69 with odds ratios of the lower score being estimated as 1.28 for Sham and 1.05 for Acupressure when compared to None.

4.9. Results related to Hospital Anxiety & Depression Scale and FACT-G scale

These were assessed at baseline and at cycles 1-4. Longitudinal linear models were fitted (Generalised Estimating Equation using unstructured covariance matrices) to the cycle 1-4 data using the relevant baseline variable as a covariate along with factors representing cycle and arm. There was no evidence of any trial arm effects on mean values as can be seen from the following Table 29.  

Table 29. Analysis of Hospital Anxiety & Depression Scale and FACT-G data by trial arm

Variable	Scale	Cycle x Arm p-value( 1)	Arm p-value(2)	Sham	Acu
Anxiety	0-21	0.34	0.48	0.11 (0.38)	-0.35 (0.37)
Depression	0-21	0.15	0.40	0.02 (0.37)	0.45 (0.36)
PWB	0-28	0.07	0.71	0.48 (0.67)	0.02 (0.66)
SFWB	0-28	0.37	0.82	-0.13 (0.46)	-0.24 (0.39)
EWB	0-24	0.80	0.77	0.05 (0.39)	0.26 (0.38)
FWB	0-28	0.39	0.86	0.11 (0.68)	0.35 (0.65)
FACT-G	0-108	0.71	0.81	0.92 (1.67)	-0.06 (1.62)
PWB: Physical well-being; SFWB: social well-being; EWB: emotional well-being; FWB: functional well-being. The last two columns show the estimated difference in means from the ‘None’ group from model (2) with standard errors in brackets. These effects are very small and non-significant.
1) Wald test from a y.baseline + cycle*arm model.
2) Wald test from a y.baseline + cycle+arm model.





4.10.	Scale reliability

A descriptive measure (Cronbach’s alpha) has been calculated at baseline. FACT scales may be calculated with 4 or more completed items. However, for Cronbach alpha analysis all items must be completed. As can be seen in Table 30, all scales used in the study had very good reliability values.


Table 30. Cronbach alpha reliability in the scales used in the trial with the current sample
Scale	N	Timepoint	N complete	Alpha
Rhodes Nausea Expression	3	Cycle 1 day 1 (day following CT)	356	0.915
Rhodes Vomiting Expression	3	Cycle 1 day 1 (day following CT)	358	0.883
Hospital Anxiety & Depression Scale: Anxiety	7	Baseline	414	0.884
Hospital Anxiety & Depression Scale: Depression	7	Baseline	420	0.824
FACT-G: PWB	7	Baseline	381	0.742
FACT-G: SFWB	7	Baseline	215	0.777
FACT-G: SFWB	6*	Baseline	377	0.844
FACT-G: EWB	6	Baseline	397	0.790
FACT-G: FWB	7	Baseline	354	0.863
FACT-G from 4 subscales	4	Baseline	363	0.743
* omitting sex life question
PWB: Physical well-being; SFWB: social well-being; EWB: emotional well-being; FWB: functional well-being.


4.11.	Wristband audit

In total 35 ‘wrist pairs’ were observed during the months August to November 2010, in the outpatients departments at four trial sites (Royal Oldham Hospital, Macclesfield District General, Liverpool Royal Hospital and Clatterbridge Centre for Oncology.

The vast majority of observations indicated that both wristbands (i.e. on both left and right wrists) were being worn correctly. In two instances the patient was observed to be wearing only one of a pair of wristbands on arrival at the outpatients department, with one patient having a swollen left arm, and the other patient having removed one wristband in advance of chemotherapy administration with the intention of wearing the wristband after the chemotherapy had been given.  Eight patients were not wearing their wristbands with one patient having swollen hands and the remaining seven patients stating that they intended to wear their wristbands after chemotherapy had been administered. Three of the six patients demonstrated how they positioned their wristbands using spare wristbands offered by the research nurse.

Only four of the sixty-eight wristbands observed (i.e. for left and right wrists) were positioned incorrectly. Three of these were worn incorrectly on the right wrist and one was incorrectly worn on the left wrist. Figure 7 below shows the distribution of wristband observations.

Figure 7: Observed wristbands during the audit (n=70)


The condition of the wristbands was also noted by the research nurses for a total of twenty-five pairs. 6 wristbands were in poor condition: two pairs of wristbands (one pair being worn for the fourth cycle and one pair being worn for the second cyclce of chemotherapy) were in generally poor condition; one pair of wristabands being worn for the third cycle of chemotherapy had loose acupressure buttons on both bands. All of these bands were replaced. Twenty-two pairs of wristbands were recorded as being in good condition. 

4.12.	Side effects from wearing the wristbands
A small number of patients in the trial reported problems regarding wearing their wristbands as follows:
 
	1 patient stated that their wristbands felt ‘too tight’ – this patient was offered larger wristbands and advised not to continue wearing the bands if the large bands also felt tight
	6 patients reported that their hands and/or arms had become swollen after receiving chemotherapy – 2 of these patients requested to try wearing larger sized bands but all patients were advised not to wear their bands whilst the swelling persisted
	1 patient reported a painful arm after receiving chemotherapy which made wearing the wristband uncomfortable – this patient was advised not to wear the wristband on the painful arm until the pain had subsided
	1 patient reported some swelling of their arms after wearing the wristbands – this patient was advised not to wear the wristbands, but was also advised that they could attempt to wear the wristbands at a later stage once swelling had subsided but to discontinue using the wristbands if swelling occurred on the second attempt of wearing the bands
	2 patients stated that they had experienced some “irritation” from wearing the wristbands – both patients were advised to discontinue wearing the wristbands
	2 patients stated that they had experienced some “sensitivity” to the wristbands – both patients were advised to discontinue wearing the wristbands
	1 patient reported that they had experienced “intolerance” to wearing the wristbands – the patient was advised to discontinue wearing the wristbands
	1 patient reported that the wristbands felt “uncomfortable” – this patient was offered a pair of large size wristbands, but these still felt “uncomfortable” so the patient was advised to stop wearing their wristbands

In all of the cases above where wristband problems had been reported patients were reminded to complete their wristband compliance questionnaires accordingly.


5.	HEALTH ECONOMICS DATA

5.1. Context of the data

5.1.1. Aim and perspective
The aim was to assess the cost-effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone. The study adopted an NHS perspective in relation to cost evaluation, in order to inform health policy relating to the use of acupressure bands in chemotherapy patients. A societal perspective for costs was adopted for a sensitivity analysis. Reporting made reference to the economic evaluation good practice62.

5.1.2. Time frame
Costs and benefits were calculated for the study period (four cycles of chemotherapy) only which was 21 days. As the trial has a time frame of less than a year neither costs or benefits were discounted.
	
5.1.3. Resource use and costs
Resource use data collected in the trial and their unit costs are presented in appendix 11. These include number of visits to the GP, practice nurse, pharmacist, health visitor, specialist nurse, consultations during hospital stays, and medication use. 

Data were collected prospectively and retrospectively using multiple sources including patient records and patient self-reported questionnaires. The questionnaires report health service utilisation subsequent to and as a result of chemotherapy-induced nausea and vomiting Direct medical costs incurred by the NHS and social services are defined as those of prophylactic or rescue antiemetic medications, drug administration devices, staff time associated with preparing and administering medication and tending to patients with chemotherapy-induced nausea and vomiting, hospitalizations due to chemotherapy-induced nausea and vomiting and hospital outpatient or GP visits due to chemotherapy-induced nausea and vomiting.  The analysis did not include costs for chemotherapy agents, pre-planned visits or hospitalizations for the purpose of chemotherapy administration, diagnostic and laboratory tests, and other patient management costs not directly related to chemotherapy-induced nausea and vomiting. The resource use questionnaire completed by patients asked them to only record health service resource usage that was as a result of chemotherapy-related nausea or vomiting.


Appendix 12 lists each of the drugs that were prescribed within the study. The Commercial Medicines Unit (CMU) electronic Market Information Tool (eMIT) was used to cost the drugs, however, when drugs were not listed on eMIT, costs were taken from the British National Formulary (BNF). Expert opinion was elicited on the standard practice for anti-emetics during chemotherapy and the standard dose for each of the drugs. As Zofran is the brand name of Ondansetron we only used this (higher) cost when it was stated that 'Zofran' was prescribed.  All other Ondansetron prescriptions were costed at the eMIT price for Ondansetron.



The total cost of each arm of the trial is calculated by combining the resource use and unit cost data along with the cost of drugs and the price of the acupressure band. There were a number of assumptions that were made when analysing the cost data. The cost of the sham acupressure band was assumed to be the same as acupressure band. If the patient did not fill in the resource use form (left it blank) we assumed that it was missing data. Hospitalisations that led to one face to face contact were assumed to represent a short stay and those with more than one face to face contact were assumed to represent a long stay.
Assumptions relating to the reported medication use are indicated below:

5.2. Assumptions made on anti-emetic use
	All patients received a standard care:

- Moderate/high emetogenic risk: 	Domperidon 20mg 4xday for 7 days 
Ondansetron IV 8mg on day of chemotherapy
Oral - 8mg 2xday for 3 days 
Dexamethasone 8mg IV on day of chemotherapy 
Oral - 8mg 1day, 4mg 1 day, 2mg 1 day 
 - Low emetogenic risk:			Domperidone 20mg 4xday 7 days

	Prolonged course = Double number of days on anti-emetic
	If form stated ‘as required’ = 7 days on stated drug
	Assumed all medication was tablet form unless stated
	Where medication details were not provided (only ‘anti-emetics given’ stated), assumed standard care
	Where doses were not recorded expert opinion was used on average normal dose of each drug 
	If not stated assume next cycle is the same as previous cycle

Societal costs
Costs from the societal perspective were calculated by combining productivity loss and loss of earnings due to work absence and out-of-pocket expenses incurred as a result chemotherapy-induced nausea and vomiting. For productivity loss we employed a human capital approach using the gross median weekly pay rate (£499) for full-time employees from the 2010 ASHE (Annual Survey of Hours and Earnings) and divided this by five. This was then reduced to 80% to represent that fact that that absence from work will not lead to a proportionate loss of productivity63 giving a daily productivity loss cost of £79.84. As there was a lot of missing data it was assumed that this reflected zero costs incurred.


5.3. Outcome measurement and valuation
Participant health-related quality of life was assessed using the EQ-5D60 which was included along with the patient resource use questionnaires. Differences between the randomised groups at follow-up with respect to EQ-5D scores were investigated using non-parametric Mann Whitney U tests since the data were not normally distributed. Change scores over time were evaluated using independent T tests.
Participant responses to the EQ-5D questionnaire were converted to health-state utility values using the UK tariff values61 and an area under the curve approach These values were then multiplied by duration (21 days) in each health state and divided by 365 to estimate quality-adjusted life-years (QALYs). QALYs represent a quality-weighted survival value where one QALY is the equivalent of one year of full health. Average QALYs between adjacent time-points were calculated to generate smoothed estimates between time-points. QALYs were calculated thus:

TotalQALY = ((EQ5D_T1*21) + (EQ5D_T2m*21)/2) + ((EQ5D_T2m*21) + (EQ5D_T3m*21)/2) + ((EQ5D_T3m*21) + (EQ5D_T4m*21)/2) + ((EQ5D_T4m*21) + (EQ5D_T5m*21)/2))/365.

5.4. Missing data
Respondents who miss individual items of the EQ-5D are not allocated a utility index score.
The Last-Observation-Carried-Forward (LOCF) method was employed to deal with missing time-point data. In this trial there were four cycles of chemotherapy after the baseline observation. If a patient dropped out of the study after the third week,  this value was then "carried forward" and assumed to be their score for the fourth cycle missing data point. Similarly, if a patient dropped out after baseline this value was carried forward to the first cycle of chemotherapy. Scores were carried forward to one consecutive time-point only. Patients with more than one consecutive missing score were omitted from the analyses. Scores were not carried out backward – i.e. those without baseline scores did not have their first follow-up scores carried backward. The advantage to the LOCF approach is that it minimises the number of subjects who are eliminated from the analysis, and it allows the analysis to examine the trends over time, rather than focusing simply on the endpoint. Assuming that scores are expected to improve over time, LOCF may be a conservative way of dealing with missing data. A full case analysis was conducted in the sensitivity analyses where participants were excluded if they had missing scores from any time-point.

We used the same method for missing resource use data, carrying forward the last observation only once if there was missing data in the consecutive time point. Patients were omitted from the analyses if they had more than one missing time point. 

5.5. Economic evaluation
Descriptive statistics of costs and EQ-5D scores were calculated by sub-group. Parametric (student t-tests and ANOVAS) and non-parametric (Wilcoxon signed ranks, Mann-Whitney and Kruskall-Wallis ANOVA tests) were conducted to evaluate differences in individual characteristics and health-related quality of life scores between groups. Mann-Whitney U tests were used to evaluate significance of differences in costs between groups as this test is less likely to be influenced by outliers. For the economic evaluation only costs of patients who had a QALY value were included.

The outcome of the cost-effectiveness analyses was an incremental cost per quality-adjusted life year (QALY) 62,64. We present Incremental Cost Effectiveness Ratios (ICERs)62,64 representing the ratios of the incremental cost and incremental benefits (QALYs) between acupressure and sham acupressure,  between acupressure and standard care and between sham acupressure and standard care . The ICER represents the additional cost per one unit of outcome gained, in this case, per QALY gained for each intervention compared to its next best alternative. As a guideline rule, NICE accepts as cost-effective those interventions with an ICER of less than £20,000 per QALY. NICE states that, in general, if a treatment costs more than £30,000 per QALY, then it would not be considered cost-effective. We also present cost-effectiveness plane scatter plots illustrating the uncertainty surrounding the cost-effectiveness estimates.

The cost-effectiveness planes were derived using bootstrapping with replacement. This stochastic uncertainty analysis involved running 10000 bootstrapped estimates of the incremental costs and QALYs. The bootstrap approach is a non-parametric method that treats the original sample as though it were the population and draws multiple random samples from the original. Cost-effectiveness acceptability curves were also generated to illustrate the probability that each treatment would be cost-effective given a range of acceptable threshold values65.
Sensitivity analyses were carried out to account for uncertainty in the cost and EQ-5D values. We performed the sensitivity analysis by adding and subtracting 20% of the costs and assessing the subsequent impact on the ICERs. The value of 20% is essentially arbitrary but it was considered likely to represent any uncertainty that might exist in parameter values. We also performed a sensitivity analysis on the QALYs by conducting a full case analysis on EQ-5D scores. In contrast to the LOCF, no missing data is imputed and patients with any missing data are omitted from the analyses. Sensitivity analyses were also run based on using an average group cost for those outliers with high costs; and by adopting a societal perspective for costs, including productivity losses and lost earnings.

Net benefit values66 were generated to enable more traditional analysis of therapy efficacy. Net benefit is a composite representation of cost-effectiveness and willingness to pay that is derived by rearranging the ICER calculation and incorporating the willingness to pay threshold value (in this case the NICE (National Institute of Clinical Excellence) £20,000 per incremental QALY threshold). Net monetary benefit (NMB) is derived for each patient thus:

NMB = (20,000*QALYs) – Costs

The decision rule becomes: adopt an intervention if the net monetary benefit > 0. Since values are transformed from ratio to linear we can subsequently employ standard regression models on the data. Net benefit regression allows us to control for covariates and baseline between group differences 67. We applied the variables used for the primary endpoint regression analyses on NMB data with treatment arm included as an independent variable. Univariate ANOVA and linear regression models were generated.


5.6. Results
Data from 450 patients (157 acupressure, 146 standard care, 147 sham acupressure) were included in the base case analysis.

5.6.1. Resource use and costs
There was very little reported resource use within the trial. Thus caution should be exercised in interpreting the results as a small number of high-resource consumers or a few instances of high-cost resource use may be unduly influencing overall results. Table 31 shows the number of times each of the health service resources was used between the different arms of the trial. The acupressure group used the fewest resources and the standard care group used the most.

Table 31 – Resource use in the trial participants

Services	Acupressure	Standard care	Sham Acupressure
GP surgery visit	5	6	5
GP home visit	3	4	3
District nurse	4	11	17
Contact with oncology hotline for advice	6	11	9
Contact with hospital oncology nurse clinician for advice	9	9	6
Contact with hospital oncology clinic for advice	5	8	7
Hospital inpatient stay	10	14	9
Hospital accident and emergency department	3	1	2
Hospital general outpatient clinic	1	0	2
Other services	3	1	1
Total resource use instances	49	65	61

In terms of the total NHS resource use cost, the acupressure group used the least number of resources and also the lowest cost. Mean total drug cost (these include anti-emetics and other drugs prescribed due to chemotherapy-induced nausea and vomiting and anti-emetic use outside of the routine pathway in each arm of the trial) for the groups were £37.07 (SD= £101.72) for the acupressure group, £51.66 (SD= £150.02) for standard care group and £24.03 (SD= £18.70) for the sham acupressure group. Mean total costs (Drug costs + all other NHS costs + band cost) for the acupressure group were lower than for the standard care or sham acupressure groups (Table 32). ‘All other NHS costs’ include the resource use from Table 31. The NHS costs for the sham group appear higher than the other groups and this seems to be driven by a higher number of district nurse visits and a few patients in the sham arm of the trial having longer in-patient stays. There were no significant differences between any treatment arm in costs according to the t-tests; this was true for the whole sample as well as for the sub-sample who also had QALY data. Mean values were distorted by a small number of high cost outlying patients leading to high levels of uncertainty around the mean cost estimates. Median total costs were £30.92, £22.72 and £30.92 for the acupressure, no band and sham acupressure, respectively. Mann Whitney tests indicated that the no band group had significantly lower total costs than the acupressure and sham acupressure groups (both p<0.001); there was no significant difference in costs between acupressure and sham acupressure groups (p=0.585). No adjustments for multiple testing were considered necessary. Figure 8 shows the cost distribution for the no acupressure group and illustrates the presence of a small number of high cost outliers. A similar pattern was observed for the other two treatment arms.  

Table 32 – Costs per arm of the trial

	AcupressureMean (SD)	Standard careMean (SD)	Sham AcupressureMean (SD)
N	72	62	60
Drug cost – cycle 1	£5.47 (1.40)	£5.60 (0.65)	£5.17 (1.55)
Drug cost – cycle 2	£11.71 (36.35)	£15.36 (50.43)	£5.15 (1.55)
Drug cost – cycle 3	£9.92 (33.34)	£15.39(49.77)	£6.86(8.86)
Drug cost – cycle 4	£9.96(33.34)	£15.31 (49.80)	£6.86 (8.86)
Total drug cost	£37.07 (101.72)	£51.66 (150.02)	£24.03 (18.70)
All other NHS cost – Baseline	£2.92 (17.56)	£0.05 (0.0)	£17.29 (124.90)
All other NHS cost – cycle 1	£8.52 (34.91)	£21.73 (76.90)	£9.35 (38.74)
All other NHS cost – cycle 2	£9.78 (44.44)	£9.18 (44.48)	£13.27 (86.59)
All other NHS cost – cycle 3	£4.17 (25.80)	£16.06 (73.89)	£52.13(303.28)
All other NHS cost – cycle 4	£0.0 (0.0)	£12.50(80.47)	£37.66(283.54)
Total All other NHS cost 	£25.39 (81.07)	£59.48(171.78)	£129.69 (604.28)
Band cost	£8.20 (.00)	£0.00 (.00)	£8.20 (.00)
Total cost	£70.66 (129.75)	£111.13 (262.68)	£161.92 (604.57)






Figure 8: Total cost distribution (No acupressure group)

Table 33 includes costs from the societal perspective. Lost earnings and productivity losses to employers through sickness absence appeared higher in the standard care group compared to either of the band groups. Overall societal costs appear similar for the band groups and significantly higher (over double) for the no band standard care group. However, as with the healthcare costs, this result is partly driven by a small number of high cost, outlying individuals making robust conclusions difficult.

Table 33: Societal costs
	AcupressureMean (SD)	Standard careMean (SD)	Sham AcupressureMean (SD)
N	72	62	60
Total days out of work	1.18 (6.77)	2.82 (9.89)	0.75 (3.45)
Total lost earnings	£54.17 (391.44)	£241.42 (1068.43)	£31.50 (244.00)
Total expenditure	£0.18 (1.15)	£0.10 (0.53)	£0.00 (0.00)
Social cost – baseline	£0.00 (0.00)	£19.82 (104.46)	£0.00 (0.00)
Social cost – cycle 1	£48.95 (255.68)	£226.73 (922.55)	£19.89 (101.05)
Social cost – cycle 2	£52.70 (329.40)	£97.17 (347.41)	£25.21 (112.07)
Social cost – cycle 3	£46.95 (374.77)	£69.77 (295.67)	£27.80 (159.23)
Social cost – cycle 4	£0.00 (0.00)	£53.37 (286.99)	£18.48 (143.18)
Total Social cost 	£148.60 (925.90)	£466.87 (1490.27)	£91.38 (472.80)
Total Societal costs (social cost + healthcare costs)	£221.91 (983.56)	£578.00 (1557.79)	£253.30 (760.40)


5.6.2. Utility data
Table 34 shows the number of valid and missing EQ-5D questionnaires for each cycle between the three arms of the study when no scores are imputed and Table 35 when values are imputed.  Mean (SD) EQ-5D scores are included for each cycle. Both the acupressure and sham acupressure groups showed a slight increase in EQ-5D from baseline to cycle 4 of chemotherapy, whereas the standard care group showed a slight decrease. In general the results indicate small fluctuations in utility values throughout the trial period and 4 chemotherapy cycles making it difficult to draw conclusions about the impact of chemotherapy-induced nausea and vomiting and its treatments on generic health-related quality of life. All the observed changes were below the minimally important difference for the EQ-5D (which is estimated to range 0.1-0.1268). Table 36 includes the mean EQ-5D values for the LOCF analysis; these were the values employed in the QALY calculation. Statistical tests indicated there were no significant differences between treatment arm EQ-5D scores at baseline. This being the case, baseline adjustments were not required. At baseline 10% (7/70) of the missing EQ-5D values were excluded as a result of one missing response on the questionnaire. In cycle 1, 4% (5/140) of the missing values were due to missing one response, 2% (3/192) in cycle 2 were missing one response, 0.9% (2/229) in cycle 3 and 0.3% (1/313) in cycle 4.

Table 34 – Mean EQ-5D scores: full case scenario

Full case scenario	Acupressure	Standard care	Sham Acupressure
EQ-5D Baseline	Mean(SD)	0.764 (0.226)	0.775 (0.210)	0.774 (0.246)
	N valid (Missing)	133 (24)	126 (20)	121 (26)
EQ-5DCycle 1	Mean(SD)	0.778 (0.215)	0.784 (0.244)	0.788 (0.254)
	N valid (Missing)	110 (47)	101 (45)	99 (48)
EQ-5DCycle 2	Mean(SD)	0.788 (0.190)	0.764 (0.253)	0.799 (0.209)
	N valid (Missing)	93 (64)	89 (57)	76 (71)
EQ-5D Cycle 3	Mean(SD)	0.732 (0.334)	0.748 (0.237)	0.806 (0.249)
	Valid (Missing)	79 (78)	72 (74)	70 (77)
EQ-5D Cycle 4	Mean(SD)	0.806 (0.176)	0.752 (0.255)	0.820 (0.266)
	Valid (Missing)	53 (104)	40 (106)	44 (103)

Table 35 – Mean EQ-5D scores: LOCF imputed values

LOCF 	Acupressure	Standard care	Sham Acupressure
EQ-5D Baseline	Mean(SD)	0.764 (0.226)	0.775 (0.210)	0.774 (0.246)
	Valid (Missing)	133 (24)	126 (20)	121 (26)
EQ-5DCycle 1	Mean(SD)	0.748 (0.244)	0.765 (0.244)	0.785 (0.265)
	Valid (Missing)	148(9)	141 (5)	138 (9)
EQ-5DCycle 2	Mean(SD)	0.776 (0.217)	0.763 (0.252)	0.779 (0.255)
	Valid (Missing)	111(46)	103 (43)	104 (43)
EQ-5D Cycle 3	Mean(SD)	0.735 (0.314)	0.746 (0.249)	0.797 (0.258)
	Valid (Missing)	96 (61)	92 (54)	77 (70)
EQ-5D Cycle 4	Mean(SD)	0.763 (0.291)	0.749 (0.245)	0.806 (0.246)
	Valid (Missing)	81 (76)	73 (73)	71 (76)

Table 36 shows the mean change between baseline and follow-up for the EQ-5D between the three arms of the trial. Independent sample t-tests indicated that the changes in EQ-5D score over time were not statistically significant.

Table 36 – Mean EQ-5D change between baseline and follow-up points for the three arms of the trial

Mean EQ-5D change*	Acupressure	Standard care	Sham Acupressure
Baseline and Cycle 1	Mean	-0.0086	-0.0113	0.0209
	N	133	126	121
Baseline and Cycle 2	Mean	-0.0186	-0.0503	0.0170
	N	96	88	86
Baseline and Cycle 3	Mean	-0.0639	-0.0637	-0.0144
	N	85	79	66
Baseline and Cycle 4	Mean 	-0.0401	-0.0649	0.0050
	N	74	63	60
* Negative value is deterioration

5.6.3. Economic Evaluation Results regarding QALY gains

Table 37 shows the total costs and QALY gains for each of the three treatment arms. Differences in QALY gains between groups were minimal, and suggest only negligible health benefits of acupressure over standard care. The sham acupressure group had the highest QALY gains over the trial period with the standard care group having the lowest. Mean total cost was highest for the sham acupressure group and lowest for the acupressure group. The high standard deviations for the cost estimates indicate the presence of a few outlying individuals who incurred significant health service costs.

Table 37 – Total costs and QALY gains by treatment arm

	Acupressure Mean (SD)	Standard careMean (SD)	Sham AcupressureMean (SD)
N	72	62	60
Total QALY gain	0.270 (0.062)	0.265 (0.072)	0.283 (0.058)
Total cost	£70.66 (129.75)	£111.13 (262.68)	£161.92 (604.57)



Table 38 includes the cost-effectiveness results, showing the incremental cost and benefits as well as the ICERs for each of the arms of the trial. Interpretation should be tempered by considering the high level of uncertainty surrounding the cost estimates and the negligible between-group differences observed in QALY gains. The standard care group was dominated by  acupressure as it had higher costs and lower QALY gains. The results suggest that the acupressure might be cost-saving compared to standard care alone. The acupressure group had lower costs than the sham acupressure group, however the sham group had higher –albeit negligible- QALY gains.  

Table 38 – Cost-effectiveness results

Analysis	Incremental Costs	Incremental QALY gain	ICER
Acupressure vs Standard care	-£40.47	0.0054	-£7494.44Acupressure dominates
Acupressure vs Sham Acupressure	-£91.26	-0.012	£7359.68
Sham  Acupressure vs Standard care	£50.79	0.018	£2853.37



Table 39 shows the sensitivity analyses that were carried out as well as the results from the non-parametric bootstrapping. The analyses adding 20% to cost support the base case analysis as acupressure still dominates the standard care group. Subgroup analyses by emo risk group was not possible since very small proportion of patients were rated as high or low emo risk and a large majority were rated as moderate.

Including only patients who had completed EQ-5D scores at every time-point did not significantly change the ICERs. The mean cost and QALY gain estimates from the bootstrapping yield similar ICER results to those of the deterministic base case scenario. Acupressure still dominates standard care only and is cheaper, but marginally less effective, than the sham acupressure. Basing analyses on costs excluding outliers or including societal costs does not alter the outcome of the key comparisons.

Table 39 – Sensitivity analyses

Analysis	Incremental Cost	Incremental QALY gain	ICER
+20% cost
Acupressure vs Standard care	-£48.56	0.0054	-£8993.33Acupressure dominates
Acupressure vs Sham Acupressure	-£109.51	-0.012	£8831.61
Sham  Acupressure vs Standard care	£60.95	0.018	£3424.04
-20% cost
Acupressure vs Standard care	-£32.38	0.0054	-£5995.56Acupressure dominates
Acupressure vs Sham Acupressure	-£73.01	-0.012	£5887.74
Sham  Acupressure vs Standard care	£40.63	0.018	£2282.70
EQ-5D Full case scenario
Acupressure vs Standard care	-£111.51	0.009	-£12,319.31Acupressure dominates
Acupressure vs Sham Acupressure	-£153.92	-0.018	£8,538.87
Sham  Acupressure vs Standard care	£42.41	0.027	£1,566.25

			
			
Excluding cost outliers			
Acupressure vs Standard care	-£7.58	0.005	-£1,403.70
Acupressure vs Sham Acupressure	-£9.68	-0.012	£780.65
Sham  Acupressure vs Standard care	£2.10	0.018	£117.98
Societal cost perspective			
Acupressure vs Standard care	-£358.74	0.005	-£66,433.33 Acupressure dominates
Acupressure vs Sham Acupressure	-£34.04	-0.012	£2,745.16
Sham  Acupressure vs Standard care	-£324.70	0.018	-£18,241.57Sham acupressure dominates
Bootstrapping
Acupressure vs Standard care	-£40.64	             0.005 	-£9,025.53Acupressure dominates
Acupressure vs Sham Acupressure	-£90.26	-            0.013 	£7,163.27

Figures 9 and 10 are cost-effectiveness planes for acupressure vs standard care and for acupressure vs sham acupressure, respectively. For acupressure versus standard care only (Figure 9), the 1000 sample estimates are spread mainly in the south east and south west quadrants suggesting that acupressure is likely to be cost saving. A good proportion of iteration results are in the south east quadrant suggesting that acupressure is also likely to lead to higher quality of life –however QALY gains are minimal. For acupressure versus sham acupressure (Figure 10), most of the sample iterations lie in the south west quadrant suggesting that acupressure is less effective (leads to reduced quality of life) than sham acupressure but leads to cost savings.  


Figure 9. Cost-effectiveness planes for acupressure versus standard care





Figure 10. Cost-effectiveness planes for acupressure versus sham acupressure


Figures 11 and 12 are the cost-effectiveness acceptability curves showing the probability that each treatment is a cost-effective choice given a range of cost-effectiveness willingness to pay thresholds. Figure 11 compares standard care only with acupressure. Using the NICE threshold of £20,000 then the probability that acupressure is cost-effective is 0.70 compared to standard care only. Figure 12 compares acupressure with sham acupressure. At the NICE threshold of £20,000, sham acupressure appears more likely to be the cost-effective option (p=0.71) compared to acupressure (p=0.20). Only at low willingness to pay thresholds (<£7000) does acupressure become the most likely option to be cost-effective. However, considering the negligible QALY gains observed in the study, the low levels of resource use, low median healthcare costs and the leverage of a few high-cost outliers, any results must be treated with caution. It is difficult to make robust claims about the comparative cost-effectiveness of any of the therapy arms.







Figure 11. Cost-effectiveness acceptability curves for acupressure versus standard care


















Figure 12. Cost-effectiveness acceptability curves for all three treatments 


5.6.4. Net Monetary Benefit

Net Monetary Benefit (NMB) was calculated for each patient and was found to be generally positive. NMB means (SD) were: 5333 (1288), 5184 (1521) and 5489 (1261) for acupressure, no band and sham acupressure, respectively. Univariate ANOVA and linear regression models using age group, gender, emetogenic risk group, treatment allocation and baseline EQ-5D scores as covariates and independent variables were run to predict NMB. 

Treatment allocation was not found to be a significant predictor of NMB. Only baseline EQ-5D scores were found to be a significant contributor to the models. This is unsurprising as NMB is based partially on QALY values derived from the EQ-5D.
6.	QUALITATIVE DATA

6.1. Objectives
	To outline patients’ experiences of using acupressure wristbands.
	To outline the reasons why patients consent to take part in a clinical trial of acupressure wristbands.
	To outline patients’ experiences of taking part in a randomised controlled trial of acupressure wristbands.

6.2. Findings

6.2.1. Sample
Twenty-six patients participated. 9 patients were recruited from Greater Manchester, 9 from Merseyside, and 8 from Plymouth. 10 had received true acupressure, 9 sham acupressure and 7 no acupressure. The age range of the patients was 35-79 (mean 55), 7 were male and 19 female. 9 of the sample were classified as received chemotherapy of high emetogenic potential, 12 medium, and 5 low. Expectation of how much nausea participants expected to experience during their chemotherapy treatment ranged from 0-10 (mean 5.8), with 0 being ‘not at all’ and 10 being ‘very frequently.’ While participants’ belief that the acupressure wristbands would help manage their sickness ranged from 2 to 10 (mean 6.9), with 0 being ‘not at all’ and 10 being ‘will help me a lot.’ 

6.2.2. Themes
A. Deciding to participate:
Patients indicated that after the initial approach by members of the research team, for the majority the decision to participate was immediate. In the time before consenting to take part (24hours+) most did, however, discuss their intention to participate with significant others, typically partners and close family. Interestingly patients attending one hospital appear to have been informed that if they participated in clinical trials it generated additional funds for the hospital, which appears to have influenced some patients to participate. 

“Well part of it he [consultant] did say that obviously it would be useful but also at the same time he did explain that obviously the more people that took part then you know it helped their side of things as well, like it got funded or something.” [P318]


“I didn’t hesitate.”  [P382]

Patients identified a range of factors influencing their decision to participate in the trial of acupressure wristbands. Undoubtedly the main motivational factor influencing patients was a desire to ‘give something back’. Almost all participants expressed an awareness of the fact that without the willingness of patients to engage in research studies it would be impossible for cancer care treatments and services to advance. In particular, it was the altruistic act of attempting to improve the care of future cancer patients which motivated patients to assist in evaluating if acupressure wristbands are effective for chemotherapy related nausea ad vomiting. 


 “My reasons were as I’d had various treatments obviously associated with the diagnosis I’d had earlier that year it was partly that each time I had treatment I did reflect on people that had gone before me who from their experience and their participation in possible research that that perhaps made things easier for me in my experience. So it was a small way of trying to help for the future. That was kind of in my head, that I just wanted to try and be part of this and hopefully that would help people like me in the future.” [P358]

“Well I thought if it helps somebody else in the future that is the only way they are going to find out the answers.” [P411]

Patients were aware that chemotherapy treatment is associated with eliciting a number of adverse side-effects, including nausea and vomiting. A desire to limit their own experience of nausea and vomiting during their chemotherapy treatment was also a strong motivational factor for almost all patients. Of key importance was the fact that the those patients participating in the trial may receive wristbands in addition to the antiemetic medication they would have received as part of their conventional care.

“I just thought if I was to be going to be sick then it might be helpful.” [P318]


“Because I could see all the list of things that you have...the after effects, you get tummy upsets and stuff like that. Then I thought; well, if that’s going to help me I don’t want to keep being sick, if it does help me I’ll have a go.” [P351]


A minority of patients indicated that the lack of any perceived risk of adverse effects from taking part in the trial was also a motivational factor when deciding to participate. Some of these patients elaborated, comparing participating in the trial of acupressure wristbands with a pharmaceutical trial. Specifically, that the decision to participate would likely have been more considered, if the trial had been for a new drug as opposed to a ‘natural’ remedy, due to a perceived greater likelihood of adverse effects.  

“There would be no side effects, there would be nothing, there was, it was no detriment really…. I know you have got to help with these things, I think possibly yes [if pharmaceutical trial] I would have done but I would have had to know a lot more about it and a lot more in depth about it. [P280]


B.	Perceptions and experiences of complementary therapies:
As part of the interview process participants were asked about their views and experiences of complementary and alternative medicine (CAM). Most patients had only limited personal experience of Complementary and Alternative Medicine  treatments prior to taking part in the trial. However, a number indicated that they had received additional Complementary and Alternative Medicine treatments during their cancer treatment, such as reflexology, massage and reiki. 

Some patients were aware of the current lack of an evidence base underpinning many Complementary and Alternative Medicine treatments. Despite this patients frequently described themselves as ‘open minded’ with regards to Complementary and Alternative Medicine treatments and their effectiveness. Often citing the successful treatment of family/friends, or the long history of some of the treatments, with comments such as ‘it’s been around for years, so there must be something in it’ being common. Complementary and Alternative Medicine treatments were also perceived as being ‘natural’, ‘safe’ treatments associated with fewer side effects than conventional medicine. However, some patients, often those who had used Complementary and Alternative Medicine treatments previously, held preconceived beliefs that many Complementary and Alternative Medicine interventions were beneficial to patients; whilst others held an opinion that Complementary and Alternative Medicine treatments were of little or no benefit to patients. For some, particularly those with a belief in the effectiveness and value of Complementary and Alternative Medicine treatments, these preconceptions were identified as a further motivational factor when deciding to participate. Interestingly, some patients indicated that their involvement in the trial, or use of Complementary and Alternative Medicine during chemotherapy, had altered their perception of Complementary and Alternative Medicine. Typically, their personal experiences of using Complementary and Alternative Medicine making them more accepting of its potential value to patients. 

“I think a lot of people don't realise that it's beneficial and it helps.  So yeah I think if more people realised and realised what help it does, you think oh complementary therapy it's neither here nor there, but actually it does help you relax and you can forget about your troubles and what you’ve gone through and it's just, it's so relaxing and so nice.  You just feel as though you could, you are just a million miles away.” [P280]


“I can’t say whether it totally worked for me but for some people it must really assist them. Not it’s the way we have got to go, if it can save taking drugs, save ailments and acupuncture has been going on for quite a few years now ((laughs)) there must be something in it, for it to still keep going you know and so I have never experienced the needles or anything like that, but I understand and appreciate it must work because it is still going after what hundreds of years?” [P334]

Most patients saw the role of Complementary and Alternative Medicine as being in combination with conventional medicine. Indeed some patients indicated that they would only be accepting of Complementary and Alternative Medicine if it was provided within the NHS, or if they were advised to use it by a treating conventional healthcare practitioner. Irrespective of previously held views or experiences of Complementary and Alternative Medicine interventions, participants were near unanimous in the importance they placed on research into Complementary and Alternative Medicine. Highlighting the importance of establishing whether treatments are effective for patients to use. There was also a view amongst some, that there should be a greater integration of Complementary and Alternative Medicine therapies and conventional therapies provided within the NHS, but that this increasing integration should be underpinned by an emerging evidence base. 

“Yes I think any alternative therapy should be looked into, or to run not necessarily on it’s own but to run alongside you know, medicine.” [P219]

“I think it’s very important [research into Complementary and Alternative Medicine].  Yes.  Because I see complementary medicine as being none evasive being, as being an aid to conventional medicines, or an add-on to conventional medicines.  Yes.” [P302]


C.	Experience of taking part in the trial:
Only a couple of participants had any previous experience of taking part in research prior to agreeing to take part in the trial of acupressure wristbands. Interviewed patients typically indicated they felt they had a good understanding of the study before consenting to participate, with many recounting the written and verbal information they had received before consenting.


“Yes I knew what it entailed and it was explained to me quite well.” [P411]

Part of this process was information on the randomisation process to receive either wristbands A, wristbands B, or treatment as normal. Patients were typically pragmatic in their perception of the process, exemplified by P280 who commented ‘you are either going to be lucky if you get the wristbands and it might help, you are unlucky you don't get anything and you just carry on as you would do if you wasn't on the trial.’ However, despite this pragmatic approach many allocated to treatment as normal still indicated they felt ‘disappointment’ at not receiving wristbands.

Many participants expressed feeling daunted upon initially receiving the paperwork for the trial. As one participant stated, ‘I thought oh crumbs [laughter].  I thought oh God every day.’ However, these feelings typically subsided once patients familiarised themselves with the forms, and realised that forms were extensively duplicated. Participants generally felt included questionnaires were easy to follow, with comments like ‘pretty straight forward’ being common. Although easy to complete a few patients felt they were a little onerous, making comments such as ‘they were perhaps, perhaps a little bit too lengthy maybe.’ Patients were asked to complete forms for the first seven days following chemotherapy, and on the tenth day. Some indicated that they failed to complete all the paperwork on the designated days. In particular that lapses in memory, or poor health, led to forms sometimes being completed retrospectively. In some instances this could involve forms being completed up to one week after the date they were supposed to be completed on. It was the difficulty of completing the paperwork when experiencing the adverse effects of chemotherapy which most patients felt resulted in some patients dropping out of the trial. 

“Some of the days when I was really, really poorly with the chemo I couldn't even get out of bed to even fill it in I’ll be honest, but I knew each day how bad I was, how sick I was.  So, you know, was able to fill it in accurately because I knew that at the beginning I was so poorly and so sick and by the end of it you are kind of coming round, so I knew from as soon as I come round and I was out of bed I filled it in.” [p280]


A number of patients felt that they had experienced positive outcomes as a result of taking part in the trial. Linked to patients’ motivations for taking part, most frequent was a sense of wellbeing as a result of feeling they had completed an altruistic act and helped others. In addition, some patients felt that the process of completing the trial paperwork had been of benefit to them. Specifically, that it provided them with some control, at a time when most felt a lack of control over their cancer experience; or that they gained benefit from being able to reflect on how their symptoms had improved during previous cycles of chemotherapy. In contrast some patients indicated they’d experienced some negative effects from completing the paperwork, chiefly that reading and rating their level of nausea and vomiting at a time when they were feeling nauseous had at times worsened their experience. 

“I think taking part in the trial is quite, it makes you feel better actually because it is a useful tool and it’s going to be of use for other people in the future…… Yes because it makes you feel better doesn’t it if you feel you are contributing something.” [P250]

“I just completed the forms as requested and it was no hassle at all. And actually it helped because it was something positive to do, on certain days and ticking the boxes and all that sort of thing, I felt because I think part of having cancer is you lose control, and I am quite, the sort of person that likes to be in control and this is enabling me a little bit of control back, so that part I quite enjoyed actually.” [P317]

“I know this sounds silly, funny almost, but some of the questions actually don’t help you when you’re not feeling well. You actually go oh, I feel sick reading out how many cups sort of, you know, sick…” [P358]

D.	Experience of using the wristbands:
Those patients who were allocated to receive either true or sham wristbands during the trial were asked about their experiences of using them. Almost all patients interviewed appear to have worn the wristbands as instructed, keeping them on for at least 7 days following chemotherapy and only removing them when washing or bathing. Indeed some patients continued using the wristbands after the 7 day period, while many also continued using the wristbands after the 4 chemotherapy cycles they were participating in the trial. Patients were asked to demonstrate how they wore the bands, with all those interviewed apparently wearing the wristbands in the correct position. The exception being two patients allocated to receive sham wristbands who were found to have worm them inappropriately. In one instance the patient wore the wristbands inside out (meaning slight pressure would have been applied to the point); while in the other the patient indicated that they had manually applied pressure to acupoint P6.

Many of the patients interviewed indicated they had only experienced mild nausea or vomiting during the trial. A number of patients were pragmatic on the extent to which the wristbands were responsible for this. Highlighting the fact that there could be a number of other reasons, including their antiemetic medication, basic constitution, or just luck! However, many patients, including some sham patients, believed the wristbands to have had a positive impact on their nausea and vomiting. There was a perception and belief that the wristbands were, at least in part, responsible for the lack of nausea and vomiting they’d experienced. For some this was due to experiences during the trial, such as patients who noticed their nausea was greater if they didn’t have the wristbands on. The wristbands were not seen as being any more, or less effective, at different times of day, or at different points in the patients chemotherapy treatment. There were also no additional benefits reported from wearing the wristbands beyond the alleviation of nausea and vomiting.

“Until the trial is complete you can’t really say whether it helped you or not can you…. I wore them, yes I wore them each time I had treatment yes.  And erm… yes I feel as though I benefited from them, and I think and I possibly would have been more sick than what I was. I felt the bands did help in that respect.  Yes.” [P219]

 “I must say I think, having learnt that I didn’t used to wear them for the first 2 weeks at first, but then I would be feeling a bit sick and I would think goodness me, why am I feeling so sick and then I would put them on and it would improve and one day I was feeling sick with them on, but they weren’t in the right place ((laughs)) I was looking at them and they weren’t in the right place, so there is a reason you know, this is why I have got such belief in them now.” [P334]

Patients reported that they hadn’t experienced any restrictions from wearing the wristbands in terms of everyday activities, other than showering/bathing/washing dishes. As P297 commented “I don’t have many household chores, but no not at all, not at all. I just, take them off when I have a bath or a shower, other than that no they are not intrusive at all.” For most patients the wristbands were seen as comfortable to wear. Although a few patients reported that they had experienced minor irritations, such as the wristbands feeling tight or painful, or the wrists becoming itchy. All reported adverse side effects were generally deemed minor and acceptable. 
 
“I find sometimes my, it gets, my skin gets quite red, and they rub and I am sure it’s because they are so badly made inside, I think that is the contributing factor.” [P318]

“I did find the bobble that went into your arm painful a few times, and I sort of had to wriggle it around just sort of release the pressure on my arm just for a few minutes, rub my arm and then put it back in again.” [P334]

A number of patients highlighted the fact that they had been questioned by others, both known to them and not, regarding their wearing of the trial wristbands. For many, they were unconcerned by the views of others. As P210 commented, ‘if they don’t like it, that’s their problem….. didn’t influence me whatsoever.’ However, a few patients highlighted that they had inhibitions about wearing them in the company of others; or had received negative responses from others to their wearing of the wristbands. When asked about this, some compared the minor impact of wearing wristbands to such things as having to wear headscarves, or have surgical pointers on their body.

“It’s a, it’s a silly point but they are there all the time, so you do sort of start pulling your sleeves down because you don’t want people to see them, you know it looks rather strange walking round with two wristbands on….. Well everybody knew about them, because I, you know you chat to people and people ask you, and so, I would just tell people but if you went for a meal or if you were out somewhere socially where people didn’t know you, you would feel slightly embarrassed. These two bands, that look as though you should be in the gym.” [P302]  
Irrespective of perceptions of effectiveness, almost all patients indicated that they would recommend the wristbands to other chemotherapy patients, or to patients experiencing nausea and vomiting due to other causes.  This related to the fact that, irrespective of whether the wristbands where of benefit for nausea and vomiting, they were not associated with having any negative or adverse effects. 

“There isn’t a reason not to wear them. Personally yes. So, yes I would recommend them yes.” [P194]

7. Discussion

7.1.	Key Quantitative Findings

Despite the higher proportion of patients showing no nausea in the acupressure group, the results of the trial show that there were no statistically significant differences between the three trial arms in relation to nausea experience. Patients in both wristbands arms had a higher odds ratio in improving their nausea experience compared to standard care arm, with the sham arm having a higher odds ratio than the acupressure arm. There was a significant gender effect, with females in both wristband groups showing significant improvements compared to males. Health care utilization was lower in the wristband arms compared to standard care only. 

Other trials in the past have also shown no significant changes from the use of acupressure in relation to nausea and vomiting management during chemotherapy administration. A review by Lee et al69 examined the results of seven trials of acupressure, where four had positive results and three negative, highlighting that the overall effect of acupressure is strongly suggestive but not conclusive. No significant differences were reported in another trial of 160 women with regards to acute nausea and vomiting, although significant differences were reported with regards to delayed nausea and vomiting70. In the largest trial of its kind (n=739), Roscoe et al24 showed that patients experienced less nausea in the first day of chemotherapy in the acupressure arms, but there were no significant differences in relation to delayed symptoms. Also the authors identified a strong gender effect, with men in an acustimulation arm improving but not women, the opposite way of the results of the current trial. Roscoe et al17 also showed in a small sample of 27 patients (25 women and 2 men) no statistically significant differences in average severity of nausea were observed between acustimulation of the P6 point, sham acustimulation and standard carearms. However, the data showed a difference close to statistical significance in the severity of delayed nausea reported during active acustimulation compared to no acustimulation (P =0.06). In addition, patients took fewer antinausea pills during the active-acustimulation cycle of this experiment compared to the no-acustimulation phase (P <0 .05). Negative results have been shown in relation to acupressure and nausea/vomiting symptoms in a large trial of 340 women during labour and delivery71. In a trial of acupuncture versus sham acupuncture during radiotherapy, authors also showed less nausea and vomiting in both the real and sham acupuncture arms compared to standard care, and justified this due to non-specific effects of a general care or high patient expectancy72 which may partly explain our results too.

Key issues in most of the past studies showing positive results include the lack of standardised antiemetic use in the trial participants and inclusion of only or mostly female subjects. If our trial included only the female sub-sample, the results would have also been positive in our case. Also, it seems that the vast majority of positive studies in the literature include small sample sizes (<100 participants), whereas the negative studies (or partly negative) have much larger sample sizes; this suggests that effects observed in methodologically weaker studies cannot always be sustained when larger and more robust trials are done. Furthermore, other studies in the past have shown that expectancy24,73, age and anxiety28,29 together with the antiemetic potential of the chemotherapy are important predictors of and can affect the outcome of acupressure, but in our trial, while unidimensionally these were also important, in a multivariate model only gender showed significant effect.

Our findings suggest a placebo or non-specific effect of the intervention arms. Placebo effects are viewed as a form of interpersonal healing, distinct from spontaneous natural healing or technological healing that depends on physiologically active pharmacological products or procedures74. Alkaissi et al75 have suggested that acupressure does indeed have a placebo effect in relation to nausea after 24hrs, although correct stimulation of the P6 point is needed to observe decreased rescue antiemetic use and decreased vomiting. Research also suggests that there are different placebo responses, each of which may be influenced by different psychological and neurobiological mechanisms depending on the context the placebo is given76. The literature also shows that placebos have actual biological effects on the brain and body and are more than response biases. They conclude in their review that placebo effects reflect mind-brain-body relationships and as such we should not ‘resort to eliminative materialism or forms of dualism that completely divide the mind from the body’ (p. 586) 76.

Trials of acupressure pose a specific problem with regards to the blinding and the choice
of placebo, particularly when outcome measures are subjective. We have chosen to use the same wristbands in both the real and sham group so they can look identical, with the real acupressure groups instructed to have the button pressing the P6 point whereas the sham group were instructed to have the button away from the P6 point in the other side of the arm. We have observed during the interviews that some patients (2/9 in the sham group) that patients used the wristbands as in the real group because they had looked on the internet or saw others wearing them properly. This may have contaminated our results. It was not possible to create a different wristband that would look identical with the real ones but would have no button nor exert pressure, as they were elastic bands. As reported by Sinha et al71 (through observations from their colleagues in the department of Industrial and Manufacturing Engineering, Penn State University) elastic bands result in some pressure. This suggests that the pressure of the band in the area proximal to the P6 point, irrespective of the presence of a button pressing the P6 point, may have produced some positive results. 

Our sample had generally low levels of nausea and/or vomiting. This may be due to the fact that we have standardized antiemetic use in our study and an inclusion criterion was receiving antiemetics as per MASCC antiemetic guidelines. This low level of experienced symptoms may be a reason for not showing significant differences in the current trial, as we have shown in another observational study of nearly 1,000 patients that use of antiemetics during chemotherapy according to MASCC guidelines is associated with significantly improved nausea/vomiting symptoms77. 

A limitation of the trial may be the missing data for the primary outcome. However, the proportion of cases missing the primary outcome (28%) is of similar order to that anticipated at the design stage (33%). Originally 90% power had been planned for a standardized difference in means of around 0.48. For pragmatic reasons the study power was reduced to 80% so that it could complete in a reasonable timeframe. The attained power that the final sample size with complete data for the primary outcome (n=361) delivered was 80% for a standardized difference in means of 0.46.  Also, another limitation which needs to be carefully considered in future trials is the choice of sham wristbands, which in our case may not have been the most optimal design.

7.2.	 Health care utilization data
Although the intervention showed no statistically significant effect of acupressure over sham acupressure and no acupressure, the health economics part of the trial run concurrently with the effectiveness part of the trial. Also, through health economics analyses in negative trials it is possible intervention benefits that are not apparent in traditional efficacy endpoints may register in QALYs, as this is a different, composite outcome. Current thinking in respect of economic analyses in cases where there is no clear differential effect/effectiveness in the intervention being assessed is that a full cost effectiveness analysis is undertaken and uncertainty accounted for. Even given that the EQ-5D changes were below minimally important and not significant, and the QALY gains were minimal (for acupressure vs standard care) one cannot evaluate the cost-effectiveness without considering costs81,82. 

Mean costs resulting from NHS resource use were consistently higher for the standard care only group compared to the acupressure group; this finding was relatively robust to sensitivity analyses. However, since very little resource use was recorded in the study and results may have been unduly influenced by outliers with high costs, this finding is relatively uncertain and must be treated with caution. Results from the EQ-5D score analysis revealed no significant differences in utility changes over time between treatment arms and QALY gains throughout the study were negligible. 

The acupressure bands group appears to have reduced health care resource use whilst realising negligible improvements in quality of life compared to standard care alone. A rapid review of the literature found no studies including costs of chemotherapy-induced nausea and vomiting to the NHS, precluding comparison with previous research. Neither did the review yield any previous studies reporting EQ-5D scores for this patient group. In the present study the EQ-5D showed no differences in utility between groups. There also appeared little overall impact of chemotherapy as no utility score changes between any cycle exceeded (or came close to exceeding) the minimal important difference identified for the measure. EQ-5D scores were similar to population norms78 at the final chemotherapy cycle for the older patients but the younger patients appeared to experience a greater utility decrement relative to norms. The mean utility for both the 25-50 and ≥ 50 age groups was 0.77 after cycle four, compared to population norms of 0.90 for the 25-54 age group and 0.79 for the 55-74 age group. It is possible that the EQ-5D is not sensitive enough a measure to capture quality of life benefits that may be experienced as a result of reduced chemotherapy-induced nausea and vomiting although a cancer-specific quality of life measure (FACT-G) also failed to detect any between group differences. There is also a non-significant baseline difference in utility scores between groups which may explain differential QALY gains over the trial period.


There were several limitations in this economic evaluation. We made assumptions regarding drug doses and anti-emetics drug type due to missing data and also made assumptions regarding length of hospital stay. Assumptions were also necessary regarding the standard care of each of the patients, relying on expert opinion and assuming care was the same across centres. It is possible that more expensive (branded) anti-emetic treatments may have been used but not captured as not all prescribing information was available. Different sites may have different protocols relating to anti-emetic prescription as a standard therapy. However, the incremental cost effectiveness ratios and the resulting conclusions regarding the cost-effectiveness of acupressure were robust to sensitivity analyses and stochastic bootstrapping.

When calculating the EQ-5D missing data we employed the last observation carried forward (LOCF) approach; this method assumes that the participant's EQ-5D response would have been stable between each cycle, rather than declining or improving. It also assumes that missing values are “missing completely at random” (i.e. that the probability of dropout is not related to variables such as disease severity, symptoms, or drug side effects). As such, the LOCF method may lead to bias in the results. However, assumptions about both costs and utility were tested in the sensitivity analyses. Finally, it is possible that the EQ-5D is an inappropriate measure to capture health benefits incurred as a result of reduced nausea and that a cancer-specific measure may be more suitable79. However, cost-utility analyses and the EQ-5D are compliant with the NICE reference case. Future research should consider cancer-specific utility measurement and comparisons with generic utility values. As the occurrence and impact of chemotherapy-induced nausea and vomiting varies over time in relation to chemotherapy receipt, quality of life impact depends on the time of measure completion during the cycle. Thus research exploring patients’ health status on a daily basis throughout the course of a chemotherapy cycle may be warranted. Given the influence of high-cost outliers in the analyses, greater exploration of what is driving these costs and indeed whether they relate to chemotherapy-induced nausea and vomiting may be worthwhile; this may involve qualitative follow-up of high-resource use individuals.


7.3.	 Qualitative data
The nested qualitative study aimed to explore patients’ reasons for taking part in a clinical trial of acupressure wristbands, and their experiences of using acupressure wristbands and taking part in the trial of acupressure wristbands. The key findings from these data suggest that patients in the wristband arms perceived the bands to be effective and felt more in control of their nausea and vomiting experience.

The motivations which patients identified for participating in the trial are congruent with the findings of previous research. Paterson et al80 conducted a nested qualitative study exploring the experiences of patients with migraines receiving acupuncture within a randomised controlled trial. Similar to the present study, they found that patients felt acupuncture was ‘worth a try’, with patients being eager for symptom relief, and a desire to help with research for altruistic motives. Although the theme ‘giving something back’ appears to be much more prevalent within the present study. This may be a consequence of the greater morbidity associated with cancer, although further research would need to be conducted to confirm if this is the case.

Patients were largely satisfied with the organisation and running of the trial. The process of recruitment was generally perceived as straightforward and had been adequately described. Interestingly, the completion of trial paperwork was seen as being of benefit by some patients, a finding again consistent with previous research80. Where the current study findings appear to differ from previous research, is the explicit feeling of ‘wellbeing’ which many patients experienced as a direct result of knowing their actions in participating might lead to the improvement of care for future cancer patients. 

Previous qualitative research exploring the experiences of patients’ receiving treatment with acupuncture suggest patients experience a range of benefits beyond the alleviation of their presenting condition, including improvements in overall well-being, sleep pattern, and energy levels53-55. A number of patients who received wristbands in the present study indicated they had experienced only minor levels of nausea and vomiting during their chemotherapy. Some patients, both those receiving true and sham wristbands, attributing the wristbands as having had a positive impact on the level of nausea and vomiting experienced. However, none of the patients who participated in interviews associated the acupressure wristbands as eliciting benefits beyond the relief of chemotherapy related nausea and vomiting. This may suggest that a greater stimulation of acupuncture points is required to elicit these effects; or that the contextual factors within the acupuncture consultation, such as the interaction between the practitioner and patient, consultation setting etc, may work in conjunction with the stimulation of acupuncture points to elicit these expanded effects of care. 

The wristbands were not associated with any significant adverse effects, and patients found them easy to wear, and to be only associated with limited social inhibitions. Importantly patients appear to have worn the wristbands in the correct location, and for the period of time instructed. However, the data revealed that two of the nine sham wearing patients had worn their wristbands inappropriately (based on their trial arm allocation), either wearing them inside out, or applying pressure manually to the acupoint. Also of importance is the apparent delay in some patients completing the trial paperwork, relying on memory to fill the forms in. Both of these may represent confounding variables, which if generalisable to other patients in the trial, could have serious implications for the results of the trial.

7.4.	 Conclusions and research recommendations
Despite several acupressure antiemetic trials suggesting a beneficial effect, the trial heterogeneity and inconsistent findings prevented any definitive conclusions being drawn. Our study, using a strong methodological design and standardization of antiemetics, showed no significant differences in the use of acupressure wristbands for the management of nausea and vomiting during chemotherapy. Nevertheless, the somewhat improved albeit not statistically significant levels of nausea in both wristband arms need some attention as patients in both arms tended to show some improvement. However, as minimally important differences in relation to chemotherapy-related nausea and vomiting are currently not established, some caution is necessary with this comment. Also, the use of wristbands led to lower health care utilization (although this did not reach statistical significance). Bands are well-accepted, are low cost and safe additions to antiemetic drugs, but the ethical aspects of suggesting the use of potentially non-effective interventions that lead to lower health care costs and health care utilization needs some careful consideration. There is a sufficiently encouraging signal and and a suggestion of potential health resource use benefits to justify exploration of acupressure in  further trials using both no intervention and sham acupressure controls. Questions that need to be answered in the future include whether other forms of acupressure, such as regular finger acupressure or Korean hand acupressure, could be more effective than wristband acupressure. A meta-analysis of existing data on acupressure wristbands may be an appropriate way to provide a more concrete answer as to whether acupressure wristbands are effective in managing nausea and/or vomiting during chemotherapy.
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